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Mycoplasma genitalium (Mg), a sexually transmitted bacterium, may cause female reproductive 
morbidities, including pelvic inflammatory disease (PID).  As the clinical and risk profile of women with 
Mg is not well understood, we examined the characteristics of Mg among women.  Data from 586 women 
with clinically suspected PID enrolled in the PID Evaluation and Clinical Health Study were analyzed.  
Clinical, demographic, sexual and behavioral characteristics were compared between women positive and 
negative for Mg in the cervix and/or endometrium by polymerase chain reaction (PCR), and between Mg 
positive and Chlamydia trachomatis (Ct) and/or Neisseria gonorrhoeae (Gc) (Ct/Gc) positive women.  
Mg positive women had similar clinical characteristics as women without Mg and as women with Ct.  
Compared to women with Gc, women with Mg had lower pelvic pain scores (p=0.01), and were less 
likely to have cervicitis (p=0.001), erythrocyte sedimentation rate >15mm/hr (p=0.002), white blood cell 
count >10,000mm3 (p=0.02), and oral temperature >38.3°C (p=0.08).  Age <25 years (AOR 2.7, 95% CI 
1.5-5.2), douching (AOR 2.3, 95% CI 1.3-4.1), and smoking (AOR 1.8, 95% CI 1.0-3.2) were associated 
with Mg.  The demographic, sexual and behavioral characteristics were similar between Mg positive 
women and Ct/Gc positive women. 
Since Mg is associated with PID, Mg may affect pregnancy, yet the consequences of prenatal Mg 
are unknown.  Therefore, we next conducted a nested case-control study to examine the relationship 
between Mg and spontaneous abortion (SAB) among women enrolled in the Early Pregnancy Study, a 
study of violence and SAB among pregnant women presenting at an Emergency Department.  Mg was 
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measured by PCR in urine from 82 women who experienced a SAB and 134 control women.  
Characteristics of cases and controls were compared and the relationship between Mg and SAB was 
evaluated.  Mg was not associated with SAB but was associated with nulliparity (AOR 3.4, 95% CI, 1.0-
11.6), self-reported difficulty conceiving (AOR 4.8, 95% CI 0.9-25.7), and history of PID (AOR 3.9, 95% 
CI 0.9-16.1) and Ct (AOR 3.0, 95% CI 0.8-10.5). 
This dissertation yields significant public health findings by describing the clinical picture of Mg-
PID, identifying women at risk, and examining the consequences of prenatal Mg. 
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1.0  INTRODUCTION 
1.1 SPECIFIC AIMS 
M. genitalium has been associated with numerous female reproductive morbidities, including cervicitis, 
PID and tubal factor infertility.  Still, M. genitalium has not been extensively studied in women.  A gap 
exists in the research literature on the clinical features and presenting complaints of women with M. 
genitalium and the risk factors associated with M. genitalium. No studies have compared the clinical 
characteristics of and risk factors for lower and/or upper genital tract M. genitalium infection to other 
bacterial STDs.  Another understudied area is the effect of M. genitalium in pregnancy.  Therefore, the 
goal of the proposed research is to describe the clinical picture of M. genitalium female genital tract 
infection, identify women at high risk for M. genitalium, and examine the consequences of prenatal M. 
genitalium infection. 
The following research aims and hypotheses will be used to achieve this goal: 
1. To describe the clinical features of women with lower and/or upper genital tract M. 
genitalium infection in a population of women presenting with clinically suspected PID.  
We hypothesize that presenting clinical characteristics, symptoms, and pelvic pain will be 
less frequent and severe among women with M. genitalium or C. trachomatis compared 
to women with gonococcal PID.   
2. To describe the risk factors of M. genitalium infection in the lower and/or upper genital 
tract in a cohort of women with clinically suspected PID.   We hypothesize that women 
with M. genitalium will be more likely to exhibit certain characteristics, such as younger 
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age, black race, history of STDs or PID, young age at sexual debut, rare or inconsistent 
condom use, hormonal contraceptive use, douching, and drug, tobacco and alcohol use 
than women without M. genitalium.   
3. To compare the risk factors of women with M. genitalium to women with N. gonorrhoeae 
and/or C. trachomatis female genital tract infections. We hypothesize that the risk factors 
for M. genitalium will be similar to risk factors of C. trachomatis and N. gonorrhoeae.   
4. To compare early pregnancy M. genitalium urine PCR between pregnant women who 
subsequently experienced a SAB and pregnant women who maintained their pregnancies 
past 22 weeks gestation.  We hypothesize that women who experienced a SAB will be 
more likely test positive for M. genitalium than women who did not experience a SAB.  
 
1.2 BACKGROUND 
1.2.1 Mycoplasma genitalium  
1.2.1.1 Definition of M. genitalium  
Mycoplasmas (class Mollicutes) are the smallest prokaryotic organisms known (1) and are distinguishable 
from other bacteria by their minute size and genome, and total lack of cell wall (2).  Mycoplasmas have 
limited biosynthetic abilities and require sterols for growth and for membrane synthesis (1).  Several 
mycoplasmal species, including 20 species in the genus Mycoplasma and two species in the genus 
Ureaplasma, have been isolated from humans, where they usually exhibit organ and tissue specificity (2, 
3).  The primary habitats in humans are the mucous surfaces of the respiratory and urogenital tracts, the 
eyes, alimentary canal, mammary glands and joints (2).  Four mycoplasmas- Mycoplasma genitalium, M. 
hominis, Ureaplasma urealyticum (biovar 2) and U. parvum (biovar 1)- are associated with disease in the 
genitourinary tract of men and women (4).   
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M. genitalium  has the smallest genome of the mycoplasmas; a size of only 580,073 base pairs of 
DNA encoding 517 genes (1, 4).  In fact it is the smallest prokaryote capable of self-replication and its 
genome was the first of any microorganism to be fully sequenced (5).  The pear-shaped M. genitalium 
cells are characterized by a complex terminal attachment organelle, known as a ‘tip structure,’ which 
mediates attachment to eukaryotic host cells and allows for motility across surfaces (5, 7).  M. genitalium 
is distinguishable from other genitourinary mycoplasmas by its structure, energy source and its small 
genome size.   
1.2.1.2 Pathogenesis of M. genitalium 
The urogenital tract is the main site infected by M. genitalium (4), but it has been, in rare occasions, 
detected in rectal (6) and respiratory tract specimens by PCR and culture (7, 8).  Adhesion of M. 
genitalium to host cells, accomplished using a specialized tip structure that contain proteins called 
adhesions which are most often encoded by the MgPa gene, is required for colonization and infection (9).  
This property of strong adherence to cells is the first step in bringing about cellular damage and invoking 
an inflammatory cell response (10).  Evidence suggests that M. genitalium may also be able to enter host 
cells and reside intracellularly within epithelial cells using their tip structure (11).   
 Following M. genitalium infection, most of the damage to host cells is caused by the 
inflammatory response of the host immune system, and only partially caused by toxins and by-products 
produced by M. genitalium (12).  Further, M. genitalium infections may follow a chronic course, as 
demonstrated with primate and human studies.  Taylor-Robinson et al showed that all 4 female 
chimpanzees inoculated urogenitally with M. genitalium shed for 12 to 15 weeks (13).   Tosh et al used 
PCR to test vaginal and urine samples from 383 young women aged 14-17 years and urine samples from 
their 117 male partners for M. genitalium (14).  Samples were collected and tested weekly following a 
positive M. genitalium test result.  The authors found that M. genitalium shedding may persist longer than 
8-12 weeks, as 31.3% of untreated M. genitalium infections lasted over 8 weeks and 21.9% (7/32) of 
infections lasted over 12 or more weeks (14).   Cohen et al collected and tested cervical samples every 2 
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months for M. genitalium by PCR from 258 Kenyan female sex workers (15).  At enrollment, 16% of the 
women tested positive for M. genitalium (15).  After 3, 5 and 7 months, 17%, 9%, and 21% of the M. 
genitalium infections persisted despite the high prevalence of antibiotic use, including doxycycline and 
ciprofloxacin, among this study population (15).  In fact, 96% (104/107) of incident M. genitalium 
infections occurred in women who were taking antibiotics at some point during follow up (15).  Although 
re-infection might have accounted for these findings, in an analysis of 7 participants who were 
persistently infected with M. genitalium for up to 21 months, all cervical specimens tested both early and 
late during infection from the same woman contained M. genitalium of the same strain type (15).  This 
suggests that women had persistent infection and were not simply getting re-infected. 
 The chronic, persistent course of M. genitalium infection seems to be similar to infections caused 
by C. trachomatis, a sexually transmitted obligate intracellular bacterium that grows in eukaryotic 
epithelial cells.  Chlamydial infections are self-limiting, acute, low-grade persistent infections, and 
infections in women tend to be asymptomatic or nonspecific. (16).  The clinical manifestations of 
chlamydial infections represent the combined effects of tissue damage from chlamydial replication and 
inflammatory responses to C. trachomatis (16). The number of infecting organisms influences the 
magnitude of the initial inflammatory response and the likelihood of repeated infection (17).  There is 
also potential for self-induced immune damage to the host arising from chlamydial heat shock proteins or 
other antigens that are similar to host components (17).  A frequent pathologic end point of C. 
trachomatis infection is scarring of affected mucous membranes, eventually causing infertility and 
ectopic pregnancy (16). C. trachomatis infection may result in severe inflammation, particularly with 
chronic infection.  Further, repeat infections may contribute to the development of a delayed hyper-
sensitivity response, which may play an important role in chlamydial-related sequelae (18).  Recurrent 
infections may provide repetitive injury to the pelvic organs and provide more opportunities for adhesion 
formation, and thus, adverse sequelae. 
 On the other hand, M. genitalium infections are less like those caused by N. gonorrhoeae, a gram-
negative diplococcus which produces a variety of extracellular products that damage host cells at the time 
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of infection.  In humans, mucous membranes lined by columnar epithelial cells are susceptible to 
gonococcal infections, as N. gonorrhoeae adheres to mucosal cells in a process mediated by surface 
proteins (19).   Ciliary motility is impaired and destruction of ciliary cells is possible, which may promote 
further attachment of additional organisms.  N. gonorrhoeae may also cause sloughing of ciliated mucosal 
cells (20). 
1.2.1.3 Transmission of M. genitalium 
Evidence suggests that M. genitalium is sexually transmitted.  First, detection of the M. genitalium has 
been associated with a history of sexual intercourse and with increasing number of sexual partners (21, 
22).  Second, the concordance rate among female sexual partners of M. genitalium infected males has 
been high, ranging from 46 to 63% (23-25).  Third, sequence-based typing of M. genitalium has revealed 
sexual transmission.  In a study of 19 couples conducted by Hjorth et al, sequence-based typing of M. 
genitalium revealed sexual transmission, for the sequence type found in specimens from the female 
partner was identical to that found in the male partner in all the couples studied (26).  
 On the contrary, M. genitalium has been detected in women who denied ever having any sexual 
contact.  In the Manhart et al study, 2 of the 34 (0.05%) women who tested positive for M. genitalium 
denied sexually activity (22), while Tosh reported that only one of the 65 (1.5%) adolescent women who 
tested positive for M. genitalium denied sexually activity (14).  However, very few women have reported 
no sexual experience, and these small numbers do not support the concept that M. genitalium is not 
sexually transmitted.  These data could be explained by false positive tests or intentional underreporting 
of sexual activity. 
1.2.1.4 Detection of M. genitalium 
There is no routinely used method to detect M. genitalium and no commercial detection method is 
currently available.  Historically, because of its small size and growth requirements, detection of M. 
genitalium has been difficult.  It is extremely hard to culture, due to the fastidiousness and slow growth of 
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the microorganism (14).  Serology can produce false positives due to the cross-reactions between M. 
genitalium and M. pneumoniae (27) and is not routinely used for epidemiological studies.  Currently, in-
house nucleic acid amplification tests (NAAT) are the most widely used method for detecting M. 
genitalium, due to their sensitivity, specificity and rapidity.  Recent developments in PCR-based M. 
genitalium assays have allowed for more research.  These tests use amplification of portions of the DNA 
which are highly conserved in M. genitalium but not found in other species.  Assays can differ in their 
target DNA sequences, with most targeting the MgPa adhesion gene (the first gene to be sequenced) or 
the rDNA gene (there is only one copy in the M. genitalium genome) (28, 29).  PCR is inexpensive and 
faster than culture and requires only a small amount of DNA.   In addition to being less time consuming 
than culture, studies have shown that PCR is more sensitive and is better at detecting M. genitalium 
specifically (30).   
 The optimal specimen type to used for M. genitalium PCR has not been thoroughly assessed, and 
differential detection  may reflect varying bacterial loads between samples (28).  Wroblewski et al found 
that self-obtained vaginal swab specimens (91%) were more sensitive than urine (65%) or cervical swab 
(53%) for the detection of M. genitalium by PCR in samples from a population of 284 symptomatic 
women presenting at a Seattle STD clinic (28).  In contrast, Jensen et al compared the efficacy of first 
void urine (FVU) with cervical and urethral swab specimens from 776 women attending an outpatient 
STD clinic for detection of M. genitalium and C. trachomatis using in-house inhibitor-controlled PCR 
assays and found urine to be the most sensitive (31).  The urine detected more infections (88%) than 
cervical (71%) and urethral swab specimens (57%), and urine specimen was significantly more efficient 
than both the urethral (p=0.0009) and the cervical swab specimen (p=0.049) (31).   The number of 
infections detected with the cervical swab was not significantly different than the number of infections 
detected with the urethral swab (p=0.21) (31).  However, as only 88% of infections were diagnosed using 
urine samples, urine specimens could be supplemented with a cervical swab specimen to increase 
sensitivity (31). When cervical and urine samples were analyzed together, 96% of infections were 
identified (31).  Similar results were found for C. trachomatis. 
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1.2.1.5 Prevalence of M. genitalium in women 
The prevalence of M. genitalium in women has varied among studies and has been estimated between less 
than 1% and 38%, depending on the study population.  In the lower genital tract, M. genitalium tends to 
be more prevalent among STD clinic attendees (4.5% to 38%) (15, 23, 32-38) compared to the general 
population of asymptomatic women (0% to 2.8%) (14, 21, 22, 33, 38, 39) (Table 1).  Further, case-control 
studies have reported a significant difference between the prevalence of M. genitalium among STD clinic 
attendees compared to asymptomatic women (33, 38).  Tsunoe et al conducted a case-control study 
among 174 female commercial sex workers attending a Japanese STD clinic and 90 asymptomatic 
pregnant women (38).  The prevalence rate of M. genitalium detected by PCR in endocervical samples 
was significantly higher in commercial sex workers compared to the pregnant women (12.6% vs. 1.1%, 
p= 0.0016) (38).  Falk et al used PCR to test urine from 465 women attending a Swedish STD clinic and 
59 women in a cervical cancer screening program for M. genitalium (33).   They found that 5.6% (26/461) 
of the women in the STD group tested positive for M. genitalium compared to none of the women in the 
cancer screening group (p=not given) (33).  
 7 
Table 1. Prevalence of M. genitalium in the female lower genital tract among the general population and STD 
clinic attendees 
 
 
Study 
 
 
Location 
 
 
N 
 
 
Sample1 
Percentage of women 
testing positive for M. genitalium 
% 
General Population 
Hamasuna, 
2008  Japan 
 
298 Urine 2.8 
Andersen, 
2007 Denmark 
 
 
921 Vaginal 2.3 
Manhart, 
2007 U.S. 
 
 
1714 Urine 0.8 
Tosh, 
 2007 U.S. 
 
383 
Vaginal 
Urine 0.8 
Falk, 
2005 Sweden 
 
59 Urine 0 
Tsunoe, 
2000 Japan 
 
90 Endocervical 1.1 
STD Clinic Attendees 
Moi, 
2009 Norway 
 
7646 
Cervical 
Urethral 4.5 
Cohen, 
2007 Kenya 
 
299 Cervical 16 
Anagrius, 
2005 Sweden 
 
445 Endocervix 6.3 
Falk, 
2005 Sweden 
 
465 Urine 5.6 
Pepin, 
2005 Sub-Saharan Africa 
 
826 Cervical 26.3 
Manhart, 
2003 U.S. 
 
719 Cervical 7 
Casin, 
2002 France 
 
170 
Cervical 
Vaginal 
Urethral 38 
Tsunoe, 
2000 Japan 
 
174 Endocervical  12.6 
Palmer, 
1991 England 
 
 
57 
Cervical 
Vaginal  
Urethral 
 
 
17.5 
1 All samples assessed using PCR assays 
 
Fewer studies have examined at the prevalence of M. genitalium upper genital tract infections.  
The prevalence of M. genitalium in samples from women with PID has ranged from 7-16% (40-43) 
(Table 2), and PID cases are more likely to test positive for M. genitalium than women without PID (13% 
vs. 0%, p<0.001) (43).  Further, the correlation between M. genitalium lower genital tract infections and 
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M. genitalium upper genital tract infections has been high.  In the PID Evaluation and Health (PEACH) 
Study, among women with mild to moderate clinically suspected pelvic inflammatory disease, infections 
of the cervix and infection of the endometrium were highly correlated (Phi correlation 0.63, p<0.0001) 
(42).   In fact,  60% of women who tested positive in the cervix also tested positive in the endometrium 
and 74% of women who tested positive in the endometrium also tested positive in the cervix (42).  In 
another study conducted among a cohort of 299 female sex workers aged 18 to 35 years in Kenya, 52% 
(24/46) of the subjects in which M. genitalium was detected in a cervical specimen and who had an 
endometrial biopsy collected at the same visit for M. genitalium PCR testing were also positive in the 
endometrium.   No women were positive in endometrial and not in cervical specimens (15). 
 
Table 2. Prevalence of M. genitalium in women with upper genital tract infections 
Study Location Study Population Sample1 
Percentage of women testing  
positive for M. genitalium 
% 
Haggerty, 
2008 U.S. 
586 women with 
clinically suspected 
mild to moderate PID  
Cervical 
Endometrial 
15% cervix and/or endometrium 
12% cervix  
8% endometrium  
Cohen, 
2005 Kenya 
123 women with 
laparoscopically 
confirmed acute 
salpingitis  
Cervical 
Endometrial 
Fallopian 
tube 
7% overall 
3%  cervix 
1%  endometrium 
1% fallopian tube 
Simms, 
2003 England 
45 PID cases and 37 
controls Endocervical 
13% of PID cases 
0% of controls 
Cohen, 
2002 Kenya 
58 women with and 57 
women without 
endometritis  
Cervix 
Endometrium 
16% with endometritis 
2% without endometritis 
1 all samples assessed using PCR assays 
 
1.2.1.6 Prevalence of M. genitalium compared to other STDs 
Several studies have found that lower genital tract M. genitalium infections are as prevalent as C. 
trachomatis or N. gonorrhoeae (15, 22, 23, 33, 36, 38, 43); the two most frequently reported bacterial 
STDs in the U.S. (Table 3).  However, not all results have been consistent (33, 35, 38).  In women with 
PID or salpingitis, the prevalence of M. genitalium has been found to be similar or greater than that of C. 
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trachomatis and N. gonorrhoeae.  In the PEACH study, M. genitalium was as prevalent as C. trachomatis 
and N. gonorrhoeae (42).  At baseline, approximately 15% of women were infected with M. genitalium, 
14% were infected with C. trachomatis and 15% were infected with N. gonorrhoeae (42).   In Kenyan 
women with laparoscopically diagnosed acute salpingitis, M. genitalium (7%) was more prevalent than C. 
trachomatis (6%), but less prevalent than N. gonorrhoeae (15%) (41). The low prevalence of other STDs 
in some of these populations may be due to effective STD screening and treatment programs in these 
regions, which would not include M. genitalium.     
 
Table 3.  Prevalence of M. genitalium compared to the prevalence of C. trachomatis and N. gonorrhoeae in 
select populations of women 
 
 
Study 
 
 
Location 
 
 
Study Population 
M. genitalium 
prevalence 
% 
C. trachomatis 
prevalence 
% 
N. gonorrhoeae  
prevalence 
% 
Women with evidence of lower genital tract infections 
Moi, 
2009 Norway STD clinic attendees 4.5 9.5 Not assessed 
Hamasuna, 
2008 Japan General population 2.8 8.8 Not assessed 
Cohen, 
2007 Kenya Commercial sex workers 22.71 141 81 
Manhart, 
2007 U.S. General population 1.0 4.2 0.4 
Tosh, 
2007 U.S. Asymptomatic adolescents 0.8 10.2 3.8 
Anagrius, 
2005 Sweden STD clinic attendees 6.3 4.0 Not assessed 
Falk, 
2005 France STD clinic attendees 6 10 0 
Simms, 
2003 England 
Women with and without 
PID 13.3 26.7 2.2 
Tsunoe, 
2000 Japan 
Asymptomatic pregnant 
women 1.1 5.6 0.0 
Tsunoe, 
2000 Japan Commercial sex workers 6.3 19 33 
Palmer, 
1991 England STD clinic attendees 19 16 Not assessed 
Women with evidence of upper genital tract infections 
Haggerty, 
2008 U.S. Women with PID 15 14 15 
Cohen, 
2005 Kenya Women with salpingitis 7 6 17 
1 incidence, n per 100-person years 
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1.2.1.7 Co-infections of M. genitalium and C. trachomatis 
Several studies have reported dual infections of M. genitalium and C. trachomatis in women (14, 23, 32, 
33, 35, 36, 39, 41, 43, 44).  However, in the lower genital tract, the co-infection rate has generally been 
low (<5% in most studies), indicating that M. genitalium is most likely transmitted alone (Table 4).  The 
co-infection rate of M. genitalium and C. trachomatis is comparable to that of C. trachomatis and N. 
gonorrhoeae, which was about 4% in a large, multi-centered study conducted among 1,701 women in the 
U.S. (45).  Compared to the studies that found a low rate of co-infection, Casin et al found a higher rate of 
dual infections of M. genitalium and C. trachomatis in women attending a STD clinic in France (32).  The 
prevalence of M. genitalium in the lower genital tract of women also positive for C. trachomatis was high 
(43%), but did not differ significantly from that among women negative for C. trachomatis (36%) (p = 
0.7) (32).  However, it may be possible that the higher incidence of M. genitalium in this population 
compared to that of C. trachomatis (38% vs. 8%) actually indicates sensitivity issues with the PCR 
method used to detect M. genitalium and not true differences. 
 
Table 4.  Lower genital tract co-infections of M. genitalium and C. trachomatis in select populations of women 
Study Location Study Population 
 
 
N 
Percentage of women with 
M. genitalium and C. trachomatis 
% 
Moi, 
2009 Norway Women attending a STD clinic  
 
7646 0.6% 
Hamasuna, 
2008 Japan Asymptomatic female students  
 
298 1% 
Tosh, 
2007 U.S. Asymptomatic female adolescents 
 
383 5.2% 
Kataoka,  
2006 Japan Pregnant women  
 
877 7.1 % 
Angarius, 
2005 Sweden Women attending a STD clinic  
 
445 3.5% 
Falk, 
2005 Sweden Women attending a STD clinic  
 
465 1% 
Cohen, 
2005 Kenya Women with salpingitis 
 
123 < 1% 
Simms, 
2003 England Women with and without PID 
 
82 2% 
Casin,  
2002 France Women attending a STD clinic  
 
170 43% 
Palmer, 
1991 England Women attending STD clinic  
 
57 5.3% 
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Co-infections of M. genitalium and other STDs in women with upper genital tract infections have 
not been thoroughly examined.  Co-infection was very common in the PEACH Study.  Approximately 
66.2% (43/63) of M. genitalium positive women were also co-infected with N. gonorrhoeae and/or C 
trachomatis in the cervix and/or endometrium and women with M. genitalium were significantly more 
likely to be co-infected with N. gonorrhoeae and/or C trachomatis than women who tested negative for 
M. genitalium (p< 0.0001) (42).  In a case-control study conducted in Sweden, Jurstrand et al analyzed 
sera obtained from patients with clinical PID and sera from healthy pregnant women using lipid-
associated membrane protein (LAMP) enzyme immunoassay assays (EIA) (46).  Nearly 12% of the 
women with PID were seropositive for both M. genitalium and C. trachomatis, while 5% were M. 
genitalium antigen seropositive only (p=not given) (46).  However, as serology represents both current 
and past infections, women may or may not have been infected with C. trachomatis and M. genitalium 
simultaneously.  Further, co-infection may have been common in these populations of women because all 
women had clinically suspected PID, and hence, were women with a high burden of STDs in general. 
In contrast to these two studies, Simms et al found a low co-infection rate among English women 
with PID; only 2.2 % (1/45) of women tested positive for both M. genitalium and C. trachomatis in the 
lower genital tract, and none of the women had M. genitalium-N. gonorrhoeae co-infections (43).  Cohen 
et al found that among Kenyan women with acute salpingitis, none were co-infected with M. genitalium 
and N. gonorrhoeae, while C. trachomatis was identified in less than 1% (1/123) of women with cervical 
M. genitalium (41).  Co-infection in this population may have been low due to the C. trachomatis and N. 
gonorrhoeae screening and treatment programs available to this population. 
1.2.1.8 Risk factors of M. genitalium 
Given that data suggests M. genitalium is sexually transmitted, the risk factor profile of women with M. 
genitalium should be similar to women with other bacterial STDs.  Risk factors for STD acquisition and 
PID are generally similar.  Women who are younger, black, non-married, less educated, of lower 
socioeconomic status or abuse drugs or alcohol have a greater risk of STDs and PID.  Further, women 
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who report a young age at sexual debut, a greater number of sexual partners, a prior history of STD or 
PID may have an increased risk (47, 48).  Thinning of the cervical mucus plug during the estrogen phase 
of the menstrual cycle (49), surgical procedures that disrupt the cervical barrier (50), douching (51-54), 
smoking (55, 56), and using intrauterine contraceptive device (IUCD) (47) also may increase the risk of 
PID by promoting the ascension of organisms from the lower to the upper genital tract.  Oral 
contraceptives have been positively associated with STDs but negatively correlated with PID (57), as oral 
contraceptives may mask the symptoms of PID symptoms in women with endometritis (58). 
Young age is a risk factor for STDs, especially for females.  Biologically, younger females are 
more susceptible to bacterial infections than older females due to cervical ectopy.  During adolescence, 
endocervical columnar epithelial cells extend to the vaginal surface, increasing the surface area and 
increasing the number of receptive cells which may favor the growth of some mucosal pathogens (59).  
Younger women may also be at a greater risk for STDs because they may be more likely to engage in 
risky sexual behaviors, such as unprotected intercourse and multiple sexual partners. 
Non-white race is also associated with STDs (60)and BV (61).  In 2007, the rate of chlamydia 
among blacks was over 8 times higher than that of whites (1,398.7 and 162.3 cases per 100,000, 
respectively) (60) . The rates among American Indian/Alaska Natives (732.9) and Hispanics (473.2) were 
also higher than that of whites (4.5 and 2.9 times higher, respectively) (60). The rate of gonorrhea among 
blacks was 19.1 times greater than the rate among whites (34.7 cases per 100,000 population) (60). 
Gonorrhea rates were 3.1 times greater among American Indian/Alaska Natives (107.1 cases per 100,000 
population), and 2.0 times greater among Hispanics (69.2 cases per 100,000 population) than among 
whites in 2007 (60).  In the U.S., BV is more common among non-Hispanic black women (61, 62). 
There is no clear explanation as to why Blacks experience higher rates of STDs and BV.  Blacks 
may have an increased risk due to behavioral factors, such as douching, multiple sexual partners and 
condom use, or demographic factors, such as socio-economic status, which may limit access to health 
care services.  However, a study conducted by Ness et al among  900 black and 235 white women from 
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five U.S. sites to determine whether racial differences in known BV risk factors can explain why blacks 
are more likely to have BV found that black race was associated with BV, independent of demographic 
and lifestyle factors (62).  After adjustment for demographic and lifestyle factors, blacks remained at 
elevated risk for BV/intermediate flora (OR 2.2, 95% CI 1.5-3.1) (62).  Blacks were also more likely to 
have specific gonococcal or chlamydial cervicitis (OR 2.2, 95% CI 1.2-3.8) after adjustment for age, 
education, history of trichomonas, gravidity, smoking, sex with menses, hormonal contraceptive use and 
douching (62).  The authors concluded that the risk factor differences did not explain the observed racial 
disparity in the occurrence of BV or gonococcal or chlamydial cervicitis.  
Numerous behaviors are associated with an increased STD and PID risk.  Douching can create an 
environment favorable to facultative aerobes and anaerobes over the usually predominant hydrogen-
peroxide-producing lactobacilli (63).  Douching can alter the vaginal microflora, remove protective 
components from the vagina or cervix, and/or promote the ascension of microorganisms from the lower to 
the upper genital tract, all increasing a woman’s susceptibility to infection (64).  Substance use may 
increase the risk of STDs by promoting riskier behaviors, such as unprotective sex or multiple sexual 
partners.  Such behaviors can increase the chance of being exposed to an infected partner.  Smoking is 
thought to exert a biologic effect on the genital tract via compromised immunity or altered estrogen status 
(55, 65), while alternatively, smoking may mark poor health-seeking behavior.  Using oral contraceptives 
(OC) use may increase risk by promoting cervical ectopy (66) or by promoting inconsistent or no use of 
barrier methods.  However, OCs may also decrease the risk of STDs because those that use OCs may be 
more likely to have better health behaviors in general.  Clinical studies indicate that correct and consistent 
condom use can help reduce the risk of bacterial and viral STD acquisition (67). However, it can be 
difficult to measure the true effectiveness of condom use due to several biases often introduced into 
epidemiological studies, most importantly over-reporting of correct and consistent use.  
Some studies have looked at the risk factors for M. genitalium genital tract infection, but results 
have been inconsistent.  However, the high background level of many risk behaviors among STD clinic 
patients or commercial sex workers may mask or diminish the association of such factors with M. 
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genitalium (15, 34, 37).  Still, infection of the lower genital tract is a risk factor for progression to PID, so 
a better understanding of correlates associated with risk of lower genital tract infection may help 
understand the factors associated with of upper genital tract infection.  Several population-based studies 
conducted in the U.S. have examined the risk factors associated with M. genitalium lower genital tract 
infections (14, 22, 68) (Tables 5 and 6).  Manhart et al used data from a subsample of  participants in 
Wave III of the National Longitudinal Study of Adolescent Health (Add Health) to examine the potential 
risk factors of M. genitalium (22).   PCR was used to test the urine of 1714 women and 1218 men aged 18 
to 27 years (22).  M genitalium infection was strongly associated with ever having engaged in vaginal 
intercourse (Prevalence Ratio (PR) 22.5, 95% CI 4.3-116.6), and in multivariate analyses the prevalence 
of M. genitalium increased by 10% with each additional vaginal intercourse partner in the past year (PR 
1.1 per partner in the past year, 95% CI 1.0-1.2) (22).  Further, M. genitalium was more prevalent in 
individuals that ever lived with a sexual partner (PR 11.2, 95% CI 3.2-39.5), and in individuals who 
reported Black race (PR 7.2, 95% CI 2.9-17.9) and condom use during last sexual intercourse (PR 3.9, 
95% CI 1.3-11.5) (22).   M. genitalium was not associated with age, age at sexual debut, or correct and 
consistent condom use over the past year (22).  In another study conducted in the U.S., Huppert et al 
tested vaginal swabs from 331 sexually active female adolescents aged 14 to 21 years recruited from 
inner-city medical center for M. genitalium using PCR (68).  Sexual intercourse within the last 7 days was 
associated with a 2-fold increase in the odds of M. genitalium infection (OR 2.0, 95% CI 1.1-3.2), after 
adjusting for C. trachomatis (68).  M. genitalium infection was not independently associated with 
demographic variables including age, race and sexual behaviors such as inconsistent condom use, new 
sexual partner, or multiple sexual partners (68).  Tosh et al used PCR to test vaginal samples from 383 
female adolescents aged 14-17 years enrolled in urban primary health care clinics in the U.S. (14).  With 
the exception of one individual, M. genitalium was identified exclusively among individuals reporting 
history of vaginal intercourse (14).  Having a recent sexual partner (OR 1.4, 95% CI 1.2-1.7) was the only 
behavioral characteristic independently associated with M. genitalium (14).  There was no difference in 
age, race, age at first intercourse, condom use, intercourse frequency, or oral sex in the past three months 
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between those with and without M. genitalium (14).    The young age of the study participants may have 
limited these studies.  Further, none of the studies compared the risk profile of women with M. genitalium 
to women with other STDs and no attempt was made to assess the potential relationship between M. 
genitalium and non-sexual related behaviors, including alcohol and drug use, smoking and vaginal 
douching.  
 
Table 5.  Select studies of the risk factors associated with M. genitalium female lower genital tract infections 
in the general population (Part A: Study, study population, sample, risk factors examined) 
Study Study Population 
 
Sample Risk factors examined 
Huppert et al, 
2008 
331 women aged 14 to 21 years recruited 
from an urban medical center 
Endocervical # of sexual partners 
Age 
Condom use 
History of STI 
Hormonal 
contraception use 
New sexual partner 
Race 
Manhart et al,  
2007  
1218 men and 1714 women aged 18-27 in 
the general population in the U.S. 
Urine # of sexual partners 
Age  
Alcohol use 
Co-infections 
Contraception use 
Drug use 
Education level 
Employment 
Ever lived with sexual 
partner 
Gender 
History of STI 
Marital status 
Race 
Sexual activity 
Tosh et al,  
2007 
383 adolescent women aged 14-17 from 
urban primary health care clinics in the 
U.S. 
Vaginal and urine # of sexual partners 
Age 
Age at first intercourse 
Co-infections  
Condom use 
Frequency of sex 
Oral sex 
Race 
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Table 6. Select studies of the risk factors associated with M. genitalium female genital tract infections in the 
general population (Part B. Risk factors significantly associated with M. genitalium, results) 
 
Study 
 
Risk factors significantly associated with M. genitalium 
 
Results 
Huppert et al, 
2008 
 
Sexual intercourse  
 
OR1 2.0 (95% CI 1.1-3.2) 
Manhart et al,  
2007  
Race 
Ever lived with a partner 
Sexually active 
Condom use during last intercourse 
PR2 7.2 (95% CI 2.9-17.9) 
PR 11.2 (95% CI 3.2-39.5) 
PR 22.5 (95% CI 4.3-116.6) 
PR 3.9 (95% CI 1.3-11.5) 
Tosh et al,  
2007  
 
Recent sexual partner 
 
OR 1.4 (95% CI 1.2-1.7) 
1 OR=odds ratio 
2 PR=prevalence ratio 
 
 
 
Only one published study has looked at the risk factors among women with M. genitalium upper 
genital tract infection (41).  Cohen et al used PCR to analyze cervical, endometrial, and fallopian tube 
samples from 123 women presenting at an STD clinic with laparoscopically confirmed salpingitis (41).  
Age, marital status and median number of sexual partners were not associated with M. genitalium 
infection at any site, while being HIV positive was independently associated with infection (Adjusted 
Hazard Ratio (AHR) 2.2, 95% CI 1.2-3.7) (41).  However, the analyses included women with gonorrhea 
or chlamydial infections, which may have biased the results.  More studies of the risk factors of M. 
genitalium upper genital tract infection are needed. 
1.2.1.9  Clinical features M. genitalium infections  
Previous studies have examined the characteristics and clinical manifestations of lower genital tract M. 
genitalium infections, yet the association of M. genitalium with lower tract disease in women has not been 
consistently reported, possibly reflecting differences in the population studied and criteria used to assess 
signs and symptoms at this site.  While some studies have showed an association between M. genitalium 
and cervicitis (33, 34, 37, 69), several PCR studies have failed to find a strong association between 
symptoms and M. genitalium lower genital tract infection (14, 22, 32).  Tosh et al studied 383 adolescent 
females attending a primary care clinic and found that women with M. genitalium identified in the lower 
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genital tract were no more symptomatic than uninfected women (14).  In a group of women negative for 
both C. trachomatis and N. gonorrhoeae, those who tested positive for M. genitalium were not more 
likely to have signs (presence of vaginal erythema, vulvar erythema or vaginal discharge) (p=0.33) or 
symptoms (vaginal itching, vaginal burning, dyspareunia) (p=0.35) compared to women negative for M. 
genitalium (14).  Manhart et al also found that lower genital tract M. genitalium infection was not 
associated with symptoms.  PCR was used to test the urine from 1,714 women enrolled in a population-
based study and M. genitalium infections were not associated with symptoms, as none of the participants 
who tested positive for M. genitalium reported symptoms of vaginal discharge (22).  Conversely, vaginal 
discharge was more common in women with lower genital tract M. genitalium infections compared to 
women without M. genitalium among 390 minority women with an active sexually transmitted infection 
(N. gonorrhoeae, C. trachomatis Trichomonas pallidum, or T. vaginalis) attending a public health clinic 
(70).  The results were similar after controlling for co-infection with other STDs.  However, vaginal 
discharge was the only genitourinary sign or symptom that was significantly different between women 
testing positive and women not infected (70).  Casin et al found no association between M. genitalium 
identified in lower genital tract and urinary symptoms (OR 1.3, 95% CI 0.7 to 2.5) or pelvic pain (OR 0.9, 
95% CI 0.5 to 1.7) among women attending a STD clinic (32).  These PCR studies indicate that M. 
genitalium does not produce strong symptoms in women with lower genital tract infections compared to 
women without M. genitalium.   
The clinical features of women presenting with upper genital tract M. genitalium have not been 
extensively examined. Two published studies have reported some clinical characteristics of women with 
M. genitalium upper genital tract infection (40, 41).  In a study of 115 Kenyan women presenting at a 
STD clinic, 100% of M. genitalium positive women with histologically diagnosed endometritis reported 
mild abdominal pain, compared to 68% of those with endometritis who were not M. genitalium positive 
(p=0.06) (40).   Further, 89% (8/9) of women infected with M. genitalium, compared to 53% (59/102) of 
uninfected women had easily induced cervical bleeding (p=0.08) (40), however, the difference was not 
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significant.  In another study by the same author, M. genitalium was not associated with severity of 
salpingitis (mild, moderate, or severe) by either clinical criteria or laparoscopic scoring system (41).   
Clinical characteristics of M. genitalium compared to other STDs 
Previous PCR studies indicate that M. genitalium does not produce strong symptoms in women 
with lower genital tract infections compared to women without M. genitalium and that the 
symptomatology induced by M. genitalium is similar to that seen for C. trachomatis (71).  In general, 
female genital tract C. trachomatis infections tend to be less abrupt in onset, and tend to have few or mild 
symptoms (71).  In fact, there are no genital symptoms that are specifically correlated with chlamydial 
cervical infection, (71) and it has been reported that more than 90% of women testing positive for C. 
trachomatis report no symptoms (72).  One study compared the symptoms of C. trachomatis and M. 
genitalium in the lower genital tract among 465 women either attending a STD clinic or enrolled in a 
cervical cancer screening program in Sweden.  In this study, no significant differences were reported in 
symptoms (32% v 23%, RR 1.4, 95% CI 0.6 to 3.4) or signs (71% v 50%, RR 1.4, 95% CI 0.9 to 2.3) 
between women testing for C. trachomatis and M. genitalium in the lower genital tract (33).  No studies 
have compared the characteristics of M. genitalium-PID to PID caused by other pathogens.    
1.2.1.10 Treatment of M. genitalium 
There is no current standard treatment for M. genitalium infection in women.   Numerous antibiotics have 
been used to treat infections, but with varying degrees of success.   As mycoplasmal bacteria lack a cell 
wall, they are therefore resistant to cell-wall-inhibiting antibiotics, including penicillin and cephalosporin 
(73).  Also, because M. genitalium grows very slowly, a longer period of therapy may be required (74).  
Further, as M. genitalium can invade epithelial cells, antibiotics may fail to fully eradicate infections, 
demonstrated by the fact that M. genitalium is associated with persistent non-gonococcal urethritis among 
men treated with tetracyclines (75).   An M. genitalium strain with increased tetracycline resistance has 
also been isolated (76), and it has been shown that other genital mycoplasmas, M. hominis and U. 
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ureaplasma, which belong to the same class as M. genitalium,  have genes coding for tetracycline 
resistance (77).  M. genitalium has demonstrated variable resistance to fluroquinolones, and susceptibility 
to macrolides, although azithromycin resistant strains have recently been identified (76, 78).   
Randomized clinical trials assessing alternative regimens for the treatment of M. genitalium are clearly 
needed. 
The efficacy of commonly used PID antimicrobials in treating M. genitalium upper genital tract 
infection is largely unknown, but there is evidence to suggest that cefoxitin and doxycycline, a CDC 
recommended PID treatment regimen, are not effective (42).  In the PEACH study, approximately 41% 
(23/56) of women who tested positive for M. genitalium at baseline again tested positive for M. 
genitalium at 30 days post-treatment with cefoxitin and doxycycline (42).  In contrast, only 2% to 4% of 
women in the PEACH study had persistent or recurrent gonococcal or chlamydial cervicitis when retested 
at 30 days (79).  Women with M. genitalium identified in the endometrium were over 4.5 times more 
likely to experience short-term treatment failure, defined by histological identification of endometritis and 
persistent pelvic pain at the 30 day follow-up clinic visit (adjusted RR 4.6, 95% CI 1.1 – 20.1) (42).  
1.2.1.11 Sequelae associated with M. genitalium infection 
The pathogenic role of M. genitalium has been studied more extensively in men than in women.  In fact, 
M. genitalium was first discovered in the 1980s in men with non-gonococcal urethritis (80), and several 
subsequent clinical studies have shown a strong association between M. genitalium and urethritis among 
men (24, 81-87).  Men attending STD clinics, and therefore higher-risk, have been most thoroughly 
studied.  The prevalence of M. genitalium in men with urethritis has ranged from 9.4% to 29.2%, while 
M. genitalium was less prevalent in asymptomatic men in the same populations (0.8–8.5%) (23, 82, 87-
90).  Due to the development of PCR detection methods, recent studies have investigated the pathogenic 
role of M. genitalium in women.  The evidence for pathogenicity among women is suggestive but 
inconclusive.  Still, studies have implicated M. genitalium with several reproductive morbidities, 
including cervicitis, PID, infertility, and adverse pregnancy outcomes.   M. genitalium does not seem to 
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be associated with BV and few studies have examined the association between M. genitalium and 
urethritis in women. 
M. genitalium and cervicitis  
M. genitalium has been implicated as an etiological agent of cervicitis, the inflammation of the 
cervix.  Four PCR studies have shown M. genitalium to be associated with cervicitis, independent of C. 
trachomatis or N. gonorrhoeae (33, 34, 37, 69) (Table 7).  However, other studies have not found a strong 
association between M. genitalium and cervicitis.   Schlicht et al did not find a difference in the detection 
of M. genitalium in cervical swabs between college-aged sexually active women with clinical signs of 
cervicitis and asymptomatic sexually active control women (91).  Thirteen percent (5/39) of symptomatic 
women and 8% (4/50) of asymptomatic women tested positive for M. genitalium by PCR (p>0.05) (92).   
Casin et al did not find an association between M. genitalium detection in the lower genital tract by PCR 
and criteria for cervicitis (erythematous cervix, mucoplurulent cervical discharge, and presence of >10 
PMNs/HPR taken separately) in a population of 170 symptomatic women presenting at a STD clinic in 
France (32).  Further, women with cervicitis were not more likely to be positive for M. genitalium than 
women without cervicitis (42% vs. 32%, p=0.19) (32).  The samples used for M. genitalium detection, the  
use of less sensitive measures of cervicitis, the use of asymptomatic women and the failure to control for 
other STDs may have accounted for null findings of these studies. 
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 Table 7.  PCR studies of M. genitalium (Mg) and cervicitis 
 
 
 
Study 
 
 
 
Location 
 
 
 
Study Population 
 
 
 
N 
% of Women 
with cervicitis 
testing positive 
for Mg 
% of Women 
without cervicitis 
testing positive 
for Mg 
 
 
 
p-value 
Anagrius, 
 2005 U.S. STD clinic attendees 445 13.3 2.6 0.02 
Falk,  
2005  Sweden 
STD clinic attendees and 
cervical cancer screening 
program participants 524 10.2 4.0 0.021 
Pepin,  
2005 Africa Female sex workers  826 16.5 7.2 0.051 
Schlicht, 
 2004 U.S. 
Sexually active symptomatic 
and asymptomatic college 
students  89 13 8 > 0.05 
Manhart, 
 2003 U.S. STD clinic attendees 719 11 5 0.0041 
Casin,  
2002 France 
Women attending a STD 
clinic  170 42 32 0.19 
Uno,  
1997 Japan 
Women  with cervicitis 
and/or adnexititis and 
asymptomatic pregnant 
women  144 7.8 0 < 0.051 
1 independent of C. trachomatis or N. gonorrhoeae 
 
 M. genitalium and bacterial vaginosis 
BV is a syndrome in which the normal vaginal lactobacilli are partially or completely replaced by 
a mixed flora with high concentrations of anaerobic and other bacteria, including Gardneralla vaginalis, 
Mobiluncus spp, Bacteroides spp, and genital mycoplasmas (93-95).  Though BV is a polymicrobial 
condition, and several anaerobes and mycoplasmal bacteria have been associated with BV, the 
microbiologic profile of women with BV has not been completely identified.  Studies regarding the 
association between M. genitalium and BV suggest that there is not a strong relationship between M. 
genitalium and BV, and this relationship similar to that of C. trachomatis and BV. 
Keane et al found no evidence of M. genitalium lower genital tract infection in any of the 15 
women with BV, but in 12% (2/17) of women with normal vaginal flora among women attending an STD 
clinic (96).  Lu et al found no association between BV and M. genitalium among women who had 
experienced a spontaneous preterm delivery; M. genitalium was diagnosed in 20% (1/5) of women with 
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BV versus 18.5% (22/119) of women without BV (97).  In a study of 45 PID cases and 37 control women 
without PID, BV was not diagnosed in any of the women with M. genitalium (98).  Due to the small 
sample size of these studies, power may have been limited.   
Several larger studies have failed to find an association between M. genitalium and BV.  In the 
PEACH study, women with M. genitalium identified in the cervix and/or endometrium were not 
significantly more likely to have BV than women without M. genitalium (63.8% vs. 56.1%, p=0.20) (42).  
Manhart et al conducted a study among 719 STD clinic attendees in which BV was found in only 20% of 
women with M. genitalium detected with PCR, versus 33% of women without M. genitalium (p= 0.05) 
(34).  Further, women with BV were less likely to have M. genitalium than women without BV; only 
4.3% of women with BV tested positive for M. genitalium while 9.2% of women without BV tested 
positive for M. genitalium (p=0.05) (34).  Falk et al conducted a study comparing the signs and symptoms 
of 465 female STD clinic attendees with a C. trachomatis or M. genitalium infection to 59 women in a 
cancer screening program who acted as controls (33).  There was no statistically significant difference in 
the prevalence of BV between M. genitalium negative women and women who tested positive for M. 
genitalium (p=0.22) (33).   
In a handful of studies, M. genitalium has been more prevalent in women with BV compared to 
women without BV.  Palmer et al studied 57 women attending an STD clinic; M. genitalium was found in 
30% (3/10) of women with BV but in only 16% (4/16) of women without BV (36).  Oakeshott et al found 
that M. genitalium was associated with BV in a group of pregnant women presenting at prenatal visits at 
less than 10 weeks gestation (99).  Women with BV by Gram stain were more likely to test positive for 
M. genitalium in their urine than women with normal vaginal flora (p for trend=0.01) (99).  Korte et al 
found a mild non-significant association between BV and M. genitalium (70).  Women who were culture 
positive for M. genitalium and women who were PCR positive for M. genitalium were more likely to have 
BV compared to women who did not test positive for M. genitalium by either method (p=0.19, p=0.11, 
respectively) (70).    
 23 
M. genitalium and urethritis 
Although in men it has been established as a cause of nongonococcal urethritis, the 
inflammation of the urethra, few studies have examined the relationship between M. genitalium and 
urethritis in women.   Anagrius et al found a strong association between M. genitalium and urethritis 
among 445 women attending a STD clinic in Sweden (23).  Women with microscopic signs of urethritis 
and without cervicitis were more likely to test positive for M. genitalium than women without urethritis 
(8.5% vs. 2.6%, p=0.02) and M. genitalium was still significantly associated with urethritis regardless of 
concomitant cervicitis (p=0.005) (23).  Moi et al also found an association between M. genitalium and 
urethritis among 7646 women attending a STD clinic in Norway (100).  The authors found a strong 
association between detecting M. genitalium in FVU by PCR and signs of urethral inflammation (100). 
Further, women with M. genitalium detected in the FVU had a higher probability of having moderate to 
severe (>10 polymorphic mononuclear leucocytes per high-powered field) inflammation of the urethra 
compared with women who were M. genitalium negative (34% vs. 22%; p<0.001) (100).  As few studies 
have examined this, the relationship between M. genitalium and urethritis in women remains unclear. 
M. genitalium and Pelvic Inflammatory Disease 
In addition to causing infections in the lower genital tract of women, evidence from animal and 
human studies support a pathogenic role of M. genitalium in female upper genital tract infection.  Non-
human female primates inoculated with M. genitalium exhibited mild genital tract infections and 
developed endometritis and salpingitis (13, 101).  M. genitalium has been shown to be able to adhere to 
human fallopian tube epithelial cells in organ culture, resulting in damage to the ciliated cells (102).  It 
has also been shown that M. genitalium can adhere to human spermatozoa, allowing it to be carried to the 
female upper genital tract on motile sperm (103).   Further, as previously mentioned, M. genitalium has 
been associated with cervicitis (33, 34, 37, 69), which often precedes upper genital tract infection.  
Therefore, it is plausible that M. genitalium can cause PID.  In fact, M. genitalium has been identified as a 
possible etiologic agent of non-gonococcal/non-chlamydial PID (40, 42, 43, 104).  It has also been 
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detected by PCR in cervical and salpingeal samples from women with laparoscopically confirmed 
salpingitis (41) and in cervical and endometrial specimens from women with endometritis (40, 42).  
However, serological studies of M. genitalium in PID have been less conclusive (46, 105, 106).  While 
data from clinical studies indicate that 10-40% of women with gonococcal infections and 20-40% of 
women infected with C. trachomatis will develop PID if these infections remain untreated (107), the 
proportion of M. genitalium infections that cause upper tract inflammation and tissue damage remains 
unknown.  Table 8 summarizes the studies of M. genitalium and PID. 
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 Table 8. Studies of M. genitalium (Mg) and female upper genital tract infections 
Study Location Population Sample Results 
PCR Studies 
Haggerty, 
2008  
U.S. 586 women with clinically 
suspected PID  
Cervical  
Endometrial 
Mg associated with baseline endometritis 
independent of C. trachomatis and  
N. gonorrhoeae   
(OR 2.0, 95% CI 1.0 – 4.2) 
Cohen, 
2005  
Kenya 126 women with 
laparoscopically confirmed 
acute salpingitis  
Cervical 
Endometrial  
Fallopian tube 
Mg detected in cervical, endometrial, and 
fallopian tube samples 
Simms, 
2003  
England 45 women with and 37 women 
without PID  
Endocervical Cases significantly more likely to test 
positive for Mg than controls  
(13% vs. 0% controls, p<0.01) 
Cohen, 
2002  
Kenya 58 women with endometritis 
and 57 women without 
endometritis attending a STD 
clinic  
Cervical  
Endometrial  
Mg infection in the endometrium alone was 
associated with endometritis, even after 
exclusion of C. trachomatis and N. 
gonorrhoeae co-infections 
(p=0.03) 
 
Women with endometritis more likely to 
test positive for Mg in the cervix and/or 
endometrium than women without 
endometritis 
 (16% vs. 2%, p=0.02)  
Uno, 
1997 
Japan 53 women  with adnexititis and 
80 asymptomatic pregnant 
women  
Cervical Women with adnexitis more likely to test 
positive for Mg than control women  
(4.1% vs. 0%, p=not given)  
Serological Studies 
Jurstrand, 
2007   
Sweden 194 women with and 396 
women without PID 
Serum Cases not more likely to be seropositive for 
Mg compared to controls 
 (17% vs. 15%, p=xxx) 
 
No association between PID and Mg 
 (OR 1.0; 95% CI 0.6-1.7) 
Lind, 
1987 
Denmark 21 women with 
laparoscopically confirmed 
salpingitis  
Serum No association between salpingitis and Mg 
 
4.8% had a > 4-fold change in titer of Mg 
antibody 
Moller, 
1984  
Denmark 31 women with acute PID Serum   39% had  > 4-fold change in titer of Mg 
antibody 
 
 
In the PEACH study, M. genitalium was detected in 15% of women at baseline, and M. 
genitalium was significantly associated with baseline endometritis, independent of C. trachomatis and N. 
gonorrhoeae (OR 2.0, 95% CI 1.0-4.2) (42).  Further, having M. genitalium identified in the endometrium 
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at baseline was associated with both an increased risk of incident endometritis at 30 days (adjusted RR 
5.0, 95% CI 1.2-20.6) and persistent endometritis, identified histologically at both baseline and 30 days 
following treatment with cefoxitin and doxycycline (adjusted RR 4.1, 95% CI 1.4-11.9) (42).   After 
adjusting for N. gonorrhoeae and C. trachomatis, endometrial M. genitalium was associated with incident 
endometritis (adjusted RR 6.0, 95% CI 1.4 -27.1).   In a subgroup of women without N. gonorrhoeae or 
C. trachomatis, women with endometrial M. genitalium at baseline were almost 9 times as likely to have 
endometritis at 30 days (adjusted RR 8.8, 95% CI 2.0-39.6) and over 13 times as likely to have incident 
endometritis at 30 days (adjusted RR 13.4, 2.4-75.2) (42). 
In a case-control study, M. genitalium was more common among women with PID than control 
women without PID.  Simms et al analyzed endocervical samples using PCR in a case-control study 
among 82 women (45 PID cases and 37 control women undergoing tubal ligation) aged 16-46 years in 
England  and found evidence of M. genitalium infection in 13% of the PID cases and none of the controls 
(43).  Cases were significantly more likely to present with M. genitalium and/or C. trachomatis than the 
control women (p<0.001) (43).  However, the control women may have been less likely to be have a 
STD, due to their older age (43). (The median age of the cases was 25 (range 16–43), whereas that of the 
controls was 34 (range 21–45), and cases were significantly younger than the controls (p<0.001) (43). 
Two recent PCR studies have also suggested that M. genitalium is associated with both 
histologically confirmed acute endometritis and laparoscopically confirmed acute salpingitis. Cohen et al 
conducted a study among 115 Kenyan women aged 18-40 years presenting at a STD clinic with 
abdominal pain that had lasted 14 or less days (108).  M. genitalium was detected in the cervix, 
endometrium, or both in 16% (9/52) of women with histologically confirmed endometritis and in 2% 
(1/57) of women without endometritis (p=0.02) (40).  Endometrial M. genitalium infection was associated 
with endometritis, even after exclusion of N. gonorrhoeae and/or C. trachomatis co-infections (p=0.03) 
(40)  In a second study conducted in Kenya among 126 women with laparoscopically confirmed acute 
salpingitis, M. genitalium was identified by PCR in 7% of all samples, 3% of cervical samples and 1% of 
endometrium samples (41).  It was also found in a fallopian tube sample from one women (41).   
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Serological studies of M. genitalium in PID have been less conclusive (46, 105, 106).  Moller et 
al used micro-immunofluorescence to test sera from 31 women diagnosed with acute PID in Denmark, in 
whom antibodies to C. trachomatis and M. hominis could not be detected (106).  Approximately 48% of 
the samples tested had antibodies to M. genitalium, while 38.7% of patients had a 4-fold or greater change 
in titre during the one month after the onset of PID (106).  However, the authors failed to provide 
information regarding the changes in M. genitalium titre among women without PID. Using indirect 
haemagglutination and indirect immunofluorescence tests, Lind and Kristensen examined sera from 21 
women with laparoscopically confirmed salpingitis without evidence of C. trachomatis or N. 
gonorrhoeae (105).  Only 1 women (4.8%) had a 4-fold or greater change in titer (105).   Jurstrand et al 
did not find an association between serological evidence of M. genitalium and PID (46).  They used lipid-
associated membrane protein-enzyme immunoassay (LAMP-EIA) to analyze sera from 194 women 
hospitalized with clinically diagnosed PID, 246 healthy  pregnant woman, and 150 healthy female blood 
donors in Sweden aged 15 to 50 years (46).  Among women with PID, 17% (33/193) were seropositive 
for M. genitalium, while 15% (36/246) of pregnant controls and 3% (5/150) of the blood donor controls 
were seropositive (46).  However, M. genitalium antibodies were not associated with PID in univariate 
analysis (OR 1.3, 95% CI 0.7 -2.2), or after adjustment of C. trachomatis infection (OR 1.0, 95% CI 0.6-
1.7) (46).  As serology measures past infection, women could have had a current infection which would 
have remain undetected with use of serology, resulting in the null findings. 
Common sequelae of PID include infertility, recurrent PID, ectopic pregnancy and chronic pelvic 
pain (109).  Therefore, M. genitalium PID may lead to subsequent reproductive morbidity.  In the PEACH 
study, rates of infertility (22%), recurrent PID (31%), and chronic pelvic pain (42%) at follow-up were 
high among women testing positive for endometrial M. genitalium at baseline (42).  Further, women who 
tested positive for M. genitalium in the endometrium were less likely to become pregnant (ARR 0.7, 95% 
CI 0.3-1.4) or have a live birth (ARR 0.6, 95% CI 0.3-1.3) and more likely to report infertility (ARR 1.1 
95% CI 0.7-4.0), chronic pelvic pain (ARR 1.3, 95% CI 0.6-2.7) and recurrent PID (ARR1.8, 95% CI 0.8-
3.8) than women without M. genitalium  (42).  These results were found after adjusting for age, race, N. 
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gonorrhoeae, and C. trachomatis infection, suggesting that infection of M. genitalium alone is sufficient 
to cause these morbidities. Although the association between M. genitalium and these sequelae did not 
reach significance, they were in the hypothesized direction and the findings were similar with another 
reported PEACH analyses, showing that chlamydial and gonococcal upper genital tract infection was not 
associated with subsequent morbidity (110).  This could be explained by the fact that women in the 
comparison groups who did not test positive for M. genitalium, C. trachomatis or N. gonorrhoeae had 
signs and symptoms of PID, thus all women in the PEACH study were at high risk of sequelae because 
they had clinically suspected PID. 
M. genitalium and Tubal Factor Infertility 
Tubal factor infertility can follow an episode of PID if the fallopian tubes undergo cellular and 
sub-cellular damage and ciliary motion of damaged epithelial cells is reduced (18).  In the large 
Scandinavian prospective cohort studies, almost 20% of women who had at least one episode of PID 
experienced TFI (109).  Other studies have found that tubal occlusion with infertility occurs in 
approximately 11-50% of PID patients (111).   The risk of TFI increases with each episode of PID. After 
a single episode of PID, the relative risk for TFI is approximately 10%, and each subsequent episode of 
PID doubles the risk of TFI; after two episodes of PID the risk of TFI is nearly 20%, and it is 40% after 
three or more episodes (112).  The severity of inflammation has also been associated with post-PID 
infertility (mild/moderate/severe; RRs 1/1.8/5.6) (112).   
The association between M. genitalium and tubal factor infertility (TFI) has been assessed by two 
serological studies and results from these studies indicate that there is a possible association between M. 
genitalium and TFI (113, 114).  Clausen et al conducted a study among 308 infertile women and found 
that antibodies against the MgPa gene were identified more frequently among women with TFI compared 
to women with normal fallopian tubes (22% vs. 6.3%, p=0.005) (113).   Women with TFI had nearly a 4-
fold greater risk of being seropositive compared to women with normal tubes (OR 3.8, 95% CI 1.7-9.4) 
(113).  Additionally, over 27% of M. genitalium positive women were seronegative to C. trachomatis, 
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suggesting an association between M. genitalium and TFI, independent of C. trachomatis  (113).  In 
another study by the same group among 194 women attending fertility clinics,  17% (5/30) of women 
with TFI assessed by culdoscopy and/or laparoscopy had antibodies to M. genitalium, compared with 
only 4% (7/164) of women with normal tubes (p<0.01) (114).  The association between TFI and M. 
genitalium was significant (OR 4.5; 95% CI 1.3-15.2), even after adjusting for C. trachomatis and age 
(OR 4.5; 95% CI 1.2-15.6) (114).  In the same study, none of the cervical swabs analyzed for M. 
genitalium were positive, indicating that a previous infection was most likely the cause of damage to the 
fallopian tubes.  
1.2.1.12 M. genitalium in pregnancy 
Because M. genitalium may be associated with PID and TFI, it is plausible that M. genitalium can infect 
the upper genital tract during pregnancy, resulting in adverse pregnancy outcomes. The prevalence of M. 
genitalium in pregnant women has ranged from less than 1% to over 20% (44, 97, 99, 115, 116) However, 
the consequences of prenatal M. genitalium are unknown.   
Definition and causes of spontaneous abortion 
Spontaneous abortion (SAB) is the most common adverse outcome of pregnancy, occurring in an 
estimated 15% of clinically recognized pregnancies (117), and up to 50% of all pregnancies (118).  
Nearly half of SABs are due to chromosomal abnormalities (119).  However, the cause of the remaining 
50% is poorly understood.  As the percentage of SAB caused by chromosomal aberrations peaks at 11 
weeks gestation, (118) other factors are more likely to have a strong impact after 11 weeks gestation.  In 
fact, after 11 weeks gestation there are 2.9 to 3.5 times more chromosomally normal SABs (118).  
Therefore, the gestational age at the time of the SAB can provide clues about the cause.  Evidence 
suggests that lower genital tract and intrauterine infections play a role in SAB (93, 120, 121).  However, 
due to the design of many studies, it is difficult to conclude whether infectious agents cause pregnancy 
loss or if they arise secondary after loss which is caused by a non-infectious etiology.  Still, several 
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different theories have been postulated to explain how infectious agents may cause SAB, including: 1) 
toxic metabolic byproducts, endotoxin, exotoxin, or cytokines may have a direct effect on the uterus, fetus 
or placenta; 2) fetal infection may cause fetal death or severe malformation incompatible with fetal 
viability; 3) placental infection may result in placental insufficiency, with subsequent fetal death; 4) 
chronic infection of the endometrium caused by the ascension of organisms from the lower genital tract 
may interfere with implantation (122). 
M. genitalium, SAB, and other adverse pregnancy outcomes 
Few published studies have looked at M. genitalium and adverse pregnancy outcomes (Tables 9 
and 10).  In a study that aimed to identify causes of and risk factors for mucopurulent cervicitis among 
STD clinic attendees, Manhart et al reported a borderline significant association between M. genitalium 
lower genital tract infection and history of SAB (OR 2.4, 95% CI 1.0-5.8) (34).  Two PCR-based studies 
have failed to find a positive association between M. genitalium and SAB.  Oakeshott et al used PCR to 
test urine samples from 1,014 pregnant women at less than 10 weeks gestation (99).  Only 0.66% (95% CI 
0.1-1.2) of the samples tested positive for M. genitalium and 1% of the women who experienced a SAB at 
less than 16 weeks gestation tested positive for M. genitalium compared to 0.6% of women who did not 
experience a SAB (p=non-significant) (99).  Selection bias may have been introduced since participants 
were women presenting at prenatal care at less than 10 weeks gestation in general practice and family 
planning clinics and were generally at low risk for STDs.  Though Labbe et al found a higher prevalence 
among 1,014 women in Guinea-Bissau (6.2%), M. genitalium at time of pregnancy loss was not 
associated with SAB (OR 0.44, 95% CI 0.01-2.75) (116).  As the number of women with M. genitalium 
infection who miscarried was very low in these two studies, insufficient power may have limited the 
ability to detect a significant association.  Further studies are needed to assess the relationship between M. 
genitalium and SAB. 
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Table 9. Studies of M. genitalium (Mg) and adverse pregnancy outcomes (Part A: Study, location, population, 
sample size, sample, gestational week, pregnancy outcome) 
 
Study 
 
Location 
 
Population 
 
N 
 
Sample 
Gestational 
week  
Pregnancy 
Outcome 
 
Edwards, 
2006 
 
 
U.S. 
Pregnant women with signs and 
symptoms of preterm labor and intact 
membranes  
 
 
137 
 
 
Vaginal 
 
 
23-32  
 
 
PTD1 
Kataoka,  
2006 
 
Japan 
Pregnant women with singleton 
pregnancies  
 
877 
 
Vaginal 
 
<11  
PTD 
SAB2 
Oakeshott,  
2004 
 
England 
 
Pregnant women  
 
1014 
 
Urine 
 
<10 
 
SAB 
Labbe, 
2002  
 
Africa 
 
Pregnant women  
 
1014 
 
Cervical 
After delivery 
or SAB 
PTD 
SAB 
Lu,  
2001 
 
U.S. 
 
Women delivering preterm 
 
124 
 
Vaginal 
 
21-25  
 
PTD 
1 PTD= preterm delivery 
2 SAB= spontaneous abortion 
 
 
Table 10. Studies of M. genitalium (Mg) and adverse pregnancy outcomes (Part B: Overall prevalence of Mg, 
results) 
 
 
Study 
Overall 
Prevalence  
of Mg 
 
 
Results  
Edwards, 
2006 
 
20.2% 
 
Mg associated with PTD1 (OR 3.5, 95% CI 1.4-8.6) 
Kataoka,  
2006 
 
0.8% 
 
Mg  not associated with SAB2 or PTD 
Oakeshott,  
2004 
 
0.6%  
 
Cases not more likely to test positive for Mg than controls  
(0.6% vs. 1.1%, p=NS3)  
Labbe, 
2002  
 
6.2%  
Mg not associated with SAB  (OR 0.4, 95% CI 0.01-2.7) 
Mg not associated with PTD  (OR 1.4, 95% CI 0.7-2.6) 
Lu,  
2001 
 
3.9%  
 
Mg positive did not delivery at an earlier gestational age than Mg negative (p=0.62) 
1 PTD= preterm delivery 
2 SAB= spontaneous abortion 
3 NS=non-significant 
 
 
The role of M. genitalium in other adverse pregnancy outcomes is also largely unknown, 
however, it has been associated with an increased risk of preterm birth in one published study (115).  
Edwards et al tested the vaginal fluid of 137 women at 23-32 weeks of gestation with signs and symptoms 
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of preterm labor and intact membranes (115).  M. genitalium was found in over 20% of samples tested 
with PCR and was found to be independently associated with a 3-fold increase risk of spontaneous 
preterm delivery (OR 3.5, 95% CI 1.4-8.6) (115).  Other studies have not found an association between 
M. genitalium and preterm birth (44, 97, 116).  In a study of 124 women with spontaneous preterm birth, 
the occurrence of M. genitalium in the vagina at mid-trimester was infrequent; only 3.9% (5/124) of the 
samples tested positive for M. genitalium by PCR (97).  Further, women with M. genitalium did not 
deliver at an earlier gestational age than women without M. genitalium; the mean delivery gestational age 
was similar for women with a positive PCR (34.6 +/- 2.2 weeks) and a negative PCR (34.0 +/- 2.7 weeks) 
(p=0.62) (97).  Labbe et al found that M. genitalium was not significantly associated with premature 
delivery (OR 1.4, 95% CI 0.7-2.6) in a population of 1014 pregnant women in Guinea-Bissau (116).   
Kataoka et al conducted  a prospective cohort study of 877 women presenting at hospitals in Japan for 
prenatal care with singleton pregnancies at less than 11 weeks gestation to test for numerous 
mycoplasmas, including, M. genitalium, M. hominis, U. parvum, and U. urealyticum using PCR (44).  
The authors found that vaginal colonization with M. genitalium  was not associated with preterm birth, as 
none of the women who experienced a preterm birth tested positive for M. genitalium (44), while only 
0.8% of all women enrolled in the study tested positive for M. genitalium.  However, these were women 
seeking prenatal care at less than 11 weeks gestation and were at low risk for STDs in general. 
Other mycoplasmas and adverse pregnancy outcomes 
More data is available on other genital tract mycoplasmas, including U. urealyticum and M. 
hominis.  In fact, in some studies, M. hominis and U. urealyticum has been associated with preterm labor 
and delivery and chorioamnionitis, the inflammation of the fetal membranes (placenta tissue) and 
amniotic fluid (44, 66, 123-125).  Other studies have suggested that there is an increased risk of SAB in 
women testing positive for mycoplasmas (126-128).  Donders et al found that  M. hominis and U. 
urealyticum infection at less than 14 weeks gestation were independently associated with an increased 
risk of pregnancy loss before 20 weeks (RR 12.5, 95% CI 3.0-52 and RR 5.8, 95% CI 2.1-16, 
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respectively)  (128).   Berg et al found that treatment of an amniotic mycoplasmal colonization with 
erythromycin was associated with fewer mid-trimester losses after genetic amniocentesis (126); 
pregnancy loss was 11.4% (4/35) and 44.4% (4/9) (p = 0.04) in the treated and untreated groups, 
respectively.  However, preterm delivery was similar in the two groups, 19.4% and 20% (p = NS). (126).  
Naessens et al found that women with a history of SAB were more likely to test positive for ureaplasmas 
in endocervical samples than control women (p<0.05) (129). In a study of 40 women who experienced a 
SAB and 20 healthy pregnant women, U. urealyticum was isolated more often in aborted tissue and 
cervical mucus from women who experienced a SAB than control women (55.0% vs. 10.0%) (127).   
Recently, previously unclassified ureaplasmas (formally called U. urealyticum) were separated 
into two species: U. parvum (biovar 1) and U. urealyticum (biovar 2). The role of the two newly specified 
ureaplasmas in adverse pregnancy outcomes have been studied, but with conflicting results.  Kataoka et al 
found a significant association between U. parvum and preterm birth (OR 3.0, 95% CI 1.1-8.5), but not 
with M. hominis or U. urealyticum and preterm birth (44).  The authors did not assess BV.  Conversely, 
Edwards et al found that U. urealyticum but not U. parvum was associated with preterm birth (OR 2.3, 
95% CI 1.0-5.1) in a study of 137 women with signs and symptoms of preterm labor and intact 
membranes between 23 and 32 weeks gestation (115). 
However, whether these mycoplasmas are independently associated with these pregnancy 
disorders and outcomes remains controversial due to their carriage rate in the general population.  It has 
been estimated that 5-49% of all women and 43-81% of pregnant women are colonized with M. hominis 
and U. urealyticum, respectively (30).  Thus, these mycoplasmas may simply be frequent colonizers of 
the reproductive tract, and not pathogenic.  Further, as women with BV have M. hominis or U. 
urealyticum in the vagina more often as well as in larger numbers than women without BV (130), failure 
to adjust for BV may confound study results.   It is also possible that these pathogens invade the upper 
genital tract after a SAB, and therefore fetal death is not a measureable outcome. 
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C. trachomatis and SAB 
The prevalence of C. trachomatis in pregnancy has varied between 2%-30% (131).  Results from 
studies assessing the relationship between C. trachomatis infections and SAB are inconclusive.  Many of 
these studies have been conducted among women who had recurrent abortions or who had a history of 
unexplained infertility, which limit the generalizability of the findings.  Further, most of the studies relied 
on measures of past infections and did not examine current infections. Still, few studies using DNA based 
methods of detection have been conducted to examine the relationship between C. trachomatis and SAB 
and results have been inconsistent.   Among women undergoing in vitro fertilization (IVF), Witkin et al 
found a strong correlation between endocervical C. trachomatis and SAB after embryo transfer (p=0.004) 
(132).  Further, C. trachomatis was identified in more women who had SABs than women who had term 
deliveries (27.3% vs. 1.8%) (132).  As all women were asymptomatic, the authors concluded that an 
undetected C. trachomatis infection may be responsible for SAB after IVF and embryo transfer (132).  
Contrary to this, Sozio and Ness did not find a significant relationship between acute lower genital tract 
C. trachomatis infection and SAB in their nested case-control pilot study of 52 women who experienced a 
SAB and 59 control women who maintained their pregnancies (133).  3.8% (2/52) of cases and 8.5% 
(5/59) of control women tested positive for C. trachomatis in their urine by ligase chain reaction, and 
women who experienced a SAB were not significantly more likely to have C. trachomatis infection than 
controls (OR 1.8, 95% CI 0.3-10.7) (133).  Thus, the role of C. trachomatis in SAB remains unexplained.  
Serology studies have found the presence of antibodies to C. trachomatis in the sera of women 
who have experienced repeated pregnancy loss.   Licciardi et al assessed the sera from 145 women 
undergoing in-vitro fertilization and found that anti-chlamydial antibodies were found in 69% (20.29) of 
women who experienced a SAB compared to 24% (9/38) of women who did not (p<0.001) (134).  Witkin 
and Ledger tested sera from the female partners of 258 couples with unexplained infertility, no history of 
chlamydial infection, and negative cervical cultures for C. trachomatis, and found that high-titer antibody 
to C. trachomatis was associated with recurrent spontaneous abortions (135).  Forty one percent (7/17) of 
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women with three abortions and 60% (6/10) of women with four abortions had chlamydial antibodies as 
opposed to 13.5% (20/148) women with no abortions, 12.8% (6/47) of women with one abortion, and 
12.1% (4/33) of women with two abortions (p<0.01) (135). The incidence of 3 or more SABs was 31.8% 
among women with high-titer chlamydial antibodies and 7.5% among women who had seronegative 
results (p<0.001) (135).  Results from this study suggest that a chronic, “silent” infection may increase the 
risk of SAB, for none of the women had a positive C. trachomatis culture test.   
Other studies have failed to find a significant association between C. trachomatis antibodies and 
SAB.  Rae did not find a significant association between antibodies to C. trachomatis and recurrent SAB 
in a population of 106 recurrent aborters and 3890 sera from a general antenatal population (136).   
Nearly 25% (26/106) of recurrent aborters had antichlamydial antibodies compared 20.3% (788/3890) of 
the general antenatal population (p < 0.05) (136).  Sugiura-Ogasawara et al found that C. trachomatis 
antibodies were not related to pregnancy outcome in women with a history of two or more miscarriages 
(137).   Over 33% of women (10/30) positive for IgA and/or IgG antibodies to C. trachomatis and 23.9% 
(48/201) of women negative for IgA and IgG antibodies to C. trachomatis experienced a SAB (p>0.05) 
(137).  Osser and Perrson also failed to find an association between previous chlamydial infection and 
SAB, as SAB cases were not significantly more likely to have chlamydial antibodies than controls (39.3% 
vs. 33.2%) (138).  Paukku et al found no statistically significant difference in the frequencies of 
chlamydial IgG or IgA antibodies between 70 women with recurrent pregnancy loss (≥ 3 consecutive 
losses) and 134 control women (139).  Small sample sizes may have limited the power of these studies.  
Further, the generalizability of these studies is limited to recurrent aborters.   
Bacterial vaginosis, SAB and other adverse pregnancy outcomes 
BV is a common condition among pregnant women.  In fact, up to 50% of pregnant women are 
have BV (131).  BV and BV-related organisms have emerged as important infections possibly associated 
with several serious obstetrical complications.  Although results from cross-sectional studies are varied, 
(120, 140-143), several prospective cohort studies have reported that BV in early pregnancy is strongly 
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and significantly associated with a 2 to 5-fold increased risk of subsequent SAB (99, 128, 144-148).  BV 
has also been shown to be associated with an increased risk of preterm birth (143, 145, 149-152).  Two 
case-control studies have found over a 2-fold increased risk of preterm delivery among women with BV 
(143, 150), while numerous cohort studies have reported similar findings.  In fact, BV in pregnancy is 
strongly and significantly associated with up to a 7-fold increased risk of subsequent preterm delivery 
(145, 149, 151, 152). 
Additional evidence of BV and preterm delivery comes from studies among populations of 
women with a high risk of preterm delivery in which oral treatment of BV has been shown to decrease the 
rate of recurrent preterm delivery (153-155).  However, a large multi-centered randomized control trial 
failed to find a significant association between treatment of asymptomatic BV during pregnancy and 
preterm delivery (156).  The timing of therapy may contribute to the effectiveness in preventing 
subsequent pregnancy complications. Therefore, more studies are needed to assess the importance of BV 
treatment during pregnancy. 
1.2.1.13 Summary  
M. genitalium is a sexually transmitted bacterium that infects the genital tract of male and females.  In 
some populations, M. genitalium is as prevalent as C. trachomatis and N. gonorrhoeae.  M. genitalium is 
emerging as a possible etiological agent of numerous female reproductive tract morbidities, including 
cervicitis, PID, and TFI.  However, the risk factors for and clinical characteristics of M. genitalium 
infections have not been well described, and no studies have compared the clinical, demographic, and 
behavioral characteristic of women with M. genitalium to women with other STDs.  Further, the 
prevalence and consequences of prenatal M. genitalium have not been thoroughly examined. With the 
recent development of more sensitive and quicker PCR-based methods of detecting M. genitalium, more 
research is warranted.   
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 2.1 ABSTRACT 
Background: Women with pelvic inflammatory disease (PID) frequently present with a spectrum of 
symptoms.  The characteristics of non-gonococcal/non-chlamydial PID are not well described.  Our 
objective was to examine the characteristics of Mycoplasma genitalium infection among women with 
clinically suspected PID. 
Methods: We evaluated 722 women enrolled in the PID Evaluation and Clinical Health study.  Women 
with M. genitalium only were compared to women with only Neisseria gonorrhoeae or Chlamydia 
trachomatis.   
Results: Compared to women with gonococcal PID, women with M. genitalium were less likely to have 
elevated systemic inflammatory markers, including erythrocyte sedimentation rate >15mm/hr (22.7% vs. 
60.8%, p=0.002), white blood cell count >10,000 mm3 (28.6% vs. 64.6%, p=0.018), and oral temperature 
> 38.3° C (0.0% vs. 13.9%, p=0.085).  Further, they were less likely to present with mucopurulent 
cervicitis (47.4% vs. 83.3%, p=.001), elevated vaginal pH (p=0.018), and high pelvic pain score 
(p=0.014).  In contrast, women with chlamydial PID had similar signs and symptoms as women with 
infected with M. genitalium. 
Conclusions: As symptoms may be mild, women with M. genitalium may not seek PID treatment.  
Further studies are needed to assess the potential reproductive tract sequelae of M. genitalium upper 
genital tract infection. 
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2.2 INTRODUCTION 
Pelvic inflammatory disease (PID), an inflammation of the female upper genital tract caused by ascension 
of organisms from the lower genital tract, affects approximately 8% of reproductive-aged women in the 
United States at some time in their lives  (157). Serious sequelae, including recurrent PID, tubal factor 
infertility, ectopic pregnancy and chronic pelvic pain frequently follow PID (158). Approximately 30% to 
50% of PID cases are caused by the sexually transmitted pathogens Chlamydia trachomatis and Neisseria 
gonorrhoeae (79, 159, 160).  Although the etiology of PID is unknown in the majority of cases, it has 
been epidemiologically linked to bacterial vaginosis (161).  
M. genitalium has been identified as a possible etiologic agent of non-gonococcal/non-chlamydial 
PID (40, 43, 69).  It has also been detected in cervical and salpingeal samples from women with 
laparoscopically confirmed salpingitis (41) and in cervical and endometrial specimens from women with 
endometritis (40).  Because M. genitalium is extremely difficult to culture, epidemiologic studies 
assessing the role of this organism in reproductive diseases among women was dependent upon the 
development and application of PCR-based assays.  Although little is known about the clinical 
characteristics of M. genitalium PID, evidence suggests that,  like women with chlamydia, lower genital 
tract infections tend to be asymptomatic (14, 162). 
Presenting characteristics of women with PID vary and may include pelvic pain, abnormal 
vaginal discharge, bleeding, itching and/or odor.  Although the most common symptom of PID is pelvic 
pain, many women with PID may have mild or absent pain, despite evidence of infection and 
inflammation (163, 164).  The presence and severity of PID symptoms varies by microbiologic etiology, 
with chlamydial patients more likely to experience asymptomatic PID than women with gonococcal PID 
(165-168).   
The purpose of our study was to describe the clinical features of women with lower and/or upper 
genital tract M. genitalium infection in a population of women presenting with clinically suspected PID.  
We hypothesize that presenting clinical characteristics, symptoms, and pelvic pain will be less frequent 
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and severe among women with M. genitalium or C. trachomatis compared to women with gonococcal 
PID.   
2.3 METHODS 
2.3.1 Study Population 
We used data from the baseline interview of the PID Evaluation and Clinical Health Study, described in 
detail elsewhere (169). Briefly, the PEACH Study evaluated the effectiveness of inpatient versus 
outpatient treatment for PID in preventing infertility.  Between March 1996 and February 1999, non-
pregnant women between the ages of 14 and 36 years were recruited from emergency departments and 
outpatient facilities (OB/GYN clinics, sexually transmitted disease clinics, and private practices) from 
seven primary (Atlanta, GA; Birmingham, AL; Charleston, SC; Detroit, MI; Philadelphia, PA; Pittsburgh, 
PA; and Providence, RI) and six secondary sites in the U.S..  Women were eligible to participate if they 
had clinically suspected PID as defined by: 1) complaints of acute pain (<30 days); 2) a clinical finding of 
pelvic tenderness; and 3) evidence of lower genital tract inflammation.  Women were excluded from the 
study if they had severe disease requiring inpatient management, could not tolerate an outpatient regimen 
due to vomiting, had an allergy to antibiotics, experienced a delivery, abortion or gynecologic surgery 
within the past 45 days, had a prior hysterectomy, bilateral salpingectomy, or bilateral tubal ligation, had 
a tubo-ovarian abscess documented by ultrasound or laparoscope and/or had appendicitis, hemorrhagic 
ovarian cyst or other condition requiring surgery by ultrasound or laparoscopy.  Eligible women were 
informed and consented, and 831 participants were enrolled into the PEACH Study.  IRB approval was 
obtained for the parent PEACH study as well as for subsequent M. genitalium PCR testing of stored 
specimens.  For this analysis, stored cervical and endometrial specimens and M. genitalium PCR assays 
were available on a subset of 722 women. The demographic, behavioral and clinical characteristics of the 
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111 women who did not have M. genitalium PCR assays did not differ significantly from the women 
included in our analyses. 
2.3.2 Data Collection  
Baseline data were collected by trained research staff at each study center using standardized interview, 
examination, and specimen collection techniques. Information was collected on demographic 
characteristics, medical, gynecologic and sexual histories, presenting complaints, substance use, current 
medications and contraception. Cervical and vaginal swabs, endometrial biopsies, and serum and urine 
samples were obtained from participants. 
2.3.3 Detection of M. genitalium 
Previously collected cervical and endometrial samples stored at -70°C were tested for M. genitalium using 
the MgPa-IMW PCR assay targeting the MgPa gene (170).  This assay has an analytical sensitivity of 15 
genomes (170) and a high clinical sensitivity and specificity relative to TMA, another M. genitalium 
NAAT assay (28).  For all samples testing positive, a repeat MgPa PCR assay (170) was performed using 
another aliquot of the sample to rule out PCR product contamination or cross-contamination; all samples 
initially positive were verified as positive in this confirmatory test.  
2.3.4 Detection of N. gonorrhoeae and C. trachomatis  
Baseline cervical and endometrial samples were assessed for N. gonorrhoeae by culture and C. 
trachomatis by PCR at a central laboratory, as previously described (79).   
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2.3.5 Clinical Characteristics 
The following are the baseline signs and symptoms that we evaluated as potential characteristics of M. 
genitalium infection: elevated oral temperature (>38.3o C), elevated white blood cell count (>10,000 
mm3), elevated erythrocyte sedimentation rate (ESR) (>15 mm/hr), C-Reactive Protein (>5mg/dL), 
bilateral adnexal tenderness, mucopurulent cervicitis, and bacterial vaginosis (BV), defined using Gram 
stain (171) and Amsel’s criteria (172).  An oral temperature of 38.3°C was considered as clinically 
elevated.  Mucopurulent cervicitis was defined as the presence of a grossly yellow or green exudates 
observed on a swab with a specimen taken from the cervix.  Presenting complaints that we evaluated as 
potential characteristics of M. genitalium infection included: nausea or vomiting, non-menstrual vaginal 
bleeding or spotting, more prolonged or heavier menstrual bleeding than usual, vaginal bleeding during or 
after sex, abnormal vaginal discharge, more frequent urination than usual, and overall self-rated pelvic 
pain.  A pelvic pain score was calculated as the mean scores for pain at worst, on average, and in the past 
24 hours, measured on a Likert scale and multiplied by 10 (range 0-100). 
2.3.6 Statistical Methods   
The Chi-square test, Fischer’s exact test, and analysis of variance were used to evaluate the baseline 
characteristics and presenting complaints.  Women with M. genitalium identified in the cervix and/or 
endometrium and who tested negative for both N. gonorrhoeae and C. trachomatis were compared to: 1) 
women who tested positive only for N. gonorrhoeae in the cervix and/or endometrium; and 2) women 
who tested positive only for C. trachomatis in the cervix and/or endometrium.  Women who tested 
positive for only N. gonorrhoeae were also compared to women co-infected with M. genitalium and N. 
gonorrhoeae.  Similarly, women who tested positive only for C. trachomatis were compared to women 
co-infected with M. genitalium and C. trachomatis.  We also examined the differences between women 
with gonococcal PID and women with chlamydial PID.  All data were analyzed using SAS version 9.1. 
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2.4 RESULTS 
Compared to women with gonococcal PID, women with M. genitalium were generally less likely to have 
elevated systemic inflammatory markers, including erythrocyte sedimentation rates greater than 15mm/hr 
(22.7% vs. 60.8%, p=0.002), white blood cell counts greater than 10,000 mm3 (28.6% vs. 64.6%, 
p=0.018), and oral temperatures greater than or equal to 38.3° C (0.0% vs. 13.9%, p=0.085) (Table 11).  
They were also significantly less likely to present with mucopurulent cervicitis (47.4% vs. 83.3%, 
p=0.001) and an elevated vaginal pH (68.4% vs. 92.3%, p=0.018).  Further, they had significantly lower 
mean composite pain scores at baseline (p=0.014).  Compared to women testing positive for N. 
gonorrhoeae, women with M. genitalium were marginally more likely to have discharge consistent with 
BV identified upon clinical examination (57.1% vs. 34.7%, p=0.065).  The clinical characteristics of 
women with only N. gonorrhoeae were not different compared to women who tested positive for both N. 
gonorrhoeae and M. genitalium.  After adjusting for BV status (normal or intermediate vs. BV flora), 
vaginal pH was no longer significantly different between women with M. genitalium and women with N. 
gonorrhoeae (data not shown).  All other results remained the same. 
In contrast to women with N. gonorrhoeae, the clinical features of women who tested positive 
only for M. genitalium were similar to women who tested positive only for C. trachomatis.  The clinical 
characteristics of women with only C. trachomatis were not different compared to women who tested 
positive for both C. trachomatis and M. genitalium (Table 12).  The results remained the same after 
adjusting for BV (data not shown). 
Compared to women with gonococcal PID, women with C. trachomatis PID were generally less 
symptomatic and less likely to have elevated systemic inflammatory markers, including elevated oral 
temperature (0% vs. 13.9%, p=0.013) or elevated white blood cell count (22.5% vs. 64.6%, p<0.001). 
They were less likely to present with cervicitis (52.4% vs. 83.3%, p<0.001) or bilateral adnexal 
tenderness (77.8% vs. 82.4%, p=0.049), and had significantly lower mean composite pain scores 
(p=0.020). 
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2.5 DISCUSSION 
To our knowledge, this is the first study to compare the clinical characteristics of women with clinically 
suspected PID who had genital tract infections with M. genitalium, N. gonorrhoeae and/or C. 
trachomatis.  Our study suggests that like chlamydial PID, M. genitalium upper genital tract infection is 
less symptomatic than gonococcal PID.  However, it should be noted that all women in the PEACH study 
had clinically suspected PID, and therefore they all presented with some signs or symptoms.  Since the 
inclusion criteria minimized the selection of asymptomatic patients, differences in the clinical 
characteristics between women with and without M. genitalium may be muted.   It would be important to 
repeat these analyses in a population of women including symptomatic and sub-clinical or “silent” PID. 
Mucopurulent cervicitis, an elevated vaginal pH, and numerous systemic markers of 
inflammation, including an elevated oral temperature, white blood cell count and ESR, were more 
prevalent in women with N. gonorrhoeae compared to women with only M. genitalium.  Further, pelvic 
pain scores were higher among women with N. gonorrhoeae.  Women with only N. gonorrhoeae 
infections had similar clinical features as those women that tested positive for both N. gonorrhoeae and 
M. genitalium.  This suggests that in co-infections, the clinical picture of N. gonorrhoeae dominates. 
The clinical features of women presenting with upper genital tract M. genitalium infection have 
not been extensively examined.  In a study of 115 women with histologically confirmed endometritis, 
100% of women with M. genitalium reported mild abdominal pain, compared to 68% of women without 
M. genitalium (p=0.06) (108). The association of M. genitalium with lower tract disease in women has not 
been consistently reported, possibly reflecting differences in the population studied and criteria used to 
assess signs and symptoms at this site.  While some studies have showed an association between M. 
genitalium and cervicitis (33, 34, 37, 69) several PCR studies have failed to find a strong association 
between symptoms and M. genitalium lower genital tract infection (14, 22, 32).  Tosh et al studied 383 
adolescent females attending a primary care clinic and found that women with M. genitalium identified in 
the lower genital tract were no more symptomatic than uninfected women (14).  In a group of women 
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negative for both C. trachomatis and N. gonorrhoeae, those who tested positive for M. genitalium were 
not more likely to have signs (presence of vaginal erythema, vulvar erythema or vaginal discharge) 
(p=0.33) or symptoms (vaginal itching, vaginal burning, dyspareunia) (p=0.35) compared to women 
negative for M. genitalium (14).  Manhart et al also found that lower genital tract M. genitalium infection 
was not associated with symptoms.  PCR was used to test the urine from 1714 women enrolled in a 
population-based study and M. genitalium infections were not associated with symptoms, as none of the 
participants who tested positive for M. genitalium reported symptoms of vaginal discharge (22).  
Conversely, vaginal discharge was more common in women with lower genital tract M. genitalium 
infections compared to women without M. genitalium among 390 minority women with an active 
sexually transmitted infection attending a public health clinic (70).  The results were similar after 
controlling for co-infection with other STDs.  However, vaginal discharge was the only genitourinary sign 
or symptom that was significantly different between women testing positive and women not infected.  
Casin et al found no association between M. genitalium identified in lower genital and urinary symptoms 
(OR 1.34, 95% CI 0.72 to 2.50) or pelvic pain (OR 0.93, 95% CI 0.50 to 1.73) among women attending a 
STD clinic (32).  These PCR studies indicate that M. genitalium does not produce strong symptoms in 
women with lower genital tract infections compared to women without M. genitalium.  The lower 
symptomatology induced by M. genitalium is similar to that seen for C. trachomatis (71). 
Our study is unique in that we compared the clinical characteristics of lower and/or upper genital 
tract M. genitalium infection to infections caused by other known bacterial STDs.  In our study, while 
women with M. genitalium tended to be less symptomatic than women with gonococcal PID, they were 
similar to women with chlamydial PID.  No characteristics differed significantly between women with M. 
genitalium and women with C. trachomatis.  While, to our knowledge, no other study has compared the 
clinical characteristics of women with clinically suspected PID, our results are similar to a study 
comparing the symptoms of C. trachomatis and M. genitalium in the lower genital tract conducted among 
465 women either attending a STD clinic or enrolled in a cervical cancer screening program in Sweden.  
In this study, no significant differences were reported in symptoms (32% v 23%, RR 1.4, 95% CI 0.6 to 
 46 
3.4) or signs (71% v 50%, RR 1.4, 95% CI 0.9 to 2.3) between women testing for C. trachomatis and M. 
genitalium in the lower genital tract (33).   
Although women with M. genitalium infections present with fewer clinical signs and symptoms, 
there is evidence from animal and human studies supporting a pathogenic role of M. genitalium in female 
upper genital tract infection.  M. genitalium has been found to induce salpingitis experimentally in 
monkeys (173), and adheres to human fallopian tube epithelial cells in organ culture, resulting in damage 
to the ciliated cells (102).  This bacterium can adhere to human spermatozoa, potentially allowing it to be 
carried to the female upper genital tract on motile sperm (103). 
 M. genitalium PID may lead to subsequent reproductive morbidity, including infertility, recurrent 
PID and pelvic pain.  In a previous analysis of the PEACH data, Haggerty et al found that rates of short 
term treatment failure (persistent endometritis and pelvic pain post treatment with cefoxitin and 
doxycycline) (41%); infertility (22%); recurrent PID (31%); and chronic pelvic pain (42%) were high 
among women testing positive for endometrial M. genitalium at baseline (42).  These results were similar 
in a subset of women testing negative for N. gonorrhoeae and C. trachomatis. Although the association 
between M. genitalium and these sequelae did not reach significance, the findings were similar with 
previously reported PEACH analyses, showing that chlamydial and gonococcal upper genital tract 
infection was not associated with subsequent morbidity (110).  This could be explained by the fact that 
women in the comparison groups who did not test positive for M. genitalium, C. trachomatis or N. 
gonorrhoeae did have signs and symptoms of PID; thus all women in the PEACH study were at high risk 
of sequelae because they had clinically suspected PID. 
Infertility after infection with M. genitalium could result from inflammation and scaring of the 
fallopian tubes because of frequent PID treatment failure, as 44% of women who tested positive for M. 
genitalium at baseline tested positive again at 30 days-post treatment (174).  A relationship between M. 
genitalium and tubal factor infertility (TFI) has also been identified in serological studies (113).  
Specifically, M. genitalium antibodies were identified more frequently among women with TFI compared 
to women with non-tubal factor infertility (22% vs. 6%) (113).  In another serological study, 17% of 
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women with TFI had antibodies to M. genitalium, compared with only 4% of women with normal tubes 
(114).   
The ability to test for concomitant infections of C. trachomatis, N. gonorrhoeae, and BV was a 
strength of our study.  However, the unavailability of data on other pathogens may limit the interpretation 
of our findings.  It may be possible that specific BV-associated bacteria, anaerobes and other 
mycoplasmal bacteria confound our analysis.  However, adjustment for these bacteria was not possible in 
our current analyses, as only a subset of PEACH women were tested for these bacteria. 
In this study, we compared clinical characteristics and presenting complaints by microbial 
etiology among a population of women with clinically suspected PID.  As our study suggests, women 
with M. genitalium may have less symptomatic PID, which, left untreated, can lead to serious 
reproductive morbidity, including tubal factor infertility, ectopic pregnancy, chronic pelvic pain and 
recurrent PID (109).  Since the etiology of up to 70% of PID cases is unknown, and M. genitalium has 
frequently been found in women with PID, detection of the pathogen may help reduce the burden of 
untreated PID.  However, as clinical symptoms may be mild, and since PID is typically diagnosed 
through clinical suspicion, women with M. genitalium may not seek PID treatment and cases of M. 
genitalium PID may go undiagnosed.  Additional studies are needed to determine a diagnostic approach 
for M. genitalium PID and to assess the potential reproductive tract sequelae of M. genitalium upper 
genital tract infection.   
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2.6 TABLES 
Table 11. Clinical characteristics of women with M. genitalium (Mg) only, women with N. gonorrhoeae (Gc) 
only and women with M. genitalium and N. gonorrhoeae 
 
Mg+/Gc-/Ct-a
(N=22) 
n (%) 
Gc+/Mg-/Ct- 
(N=74) 
n (%) 
 
 
p-valueb 
Gc+/Mg+/Ct- 
(N=16) 
n (%) 
 
 
p-valuec 
Presenting Complaints      
     Nausea/vomiting   
     Non-menstrual vaginal bleeding 
     Heavier menstrual bleeding 
     Bleeding during or after sex 
     Abnormal vaginal discharge 
     More frequent urination  
10 (45.5) 
9 (40.9) 
10 (45.5) 
4 (18.2) 
14 (63.6) 
11 (50.0) 
30 (40.5) 
28 (37.8) 
26 (35.1) 
6 (8.1) 
50 (67.6) 
31 (41.9) 
0.682 
0.795 
0.380 
0.230 
0.731 
0.501 
8 (50.0) 
3 (18.8) 
5 (31.3) 
2 (12.5) 
8 (50.0) 
10 (62.5) 
0.487 
0.245 
0.767 
0.629 
0.183 
0.170 
Markers of Inflammation      
     Elevated temperature ( >38.3o C) 
     Elevated white blood cell count ( >10,000 mm3 ) 
     Erythrocyte Sedimentation Rate ( >15 mm/hr) 
     C-Reactive Protein ( >5mg/dL) 
     Bilateral adnexal tenderness 
0 (0.0) 
4 (28.6) 
5 (22.7) 
1 (4.5) 
17 (77.3) 
10 (13.9) 
42 (64.6) 
45 (60.8) 
9 (12.2) 
61 (82.4) 
0.085 
0.018 
0.002 
0.305 
0.586 
1 (6.67) 
5 (41.7) 
8 (50.0) 
2 (12.5) 
15 (93.8) 
0.681 
0.134 
0.426 
0.970 
0.257 
Mucopurulent cervicitis 9 (47.4) 60 (83.3) 0.001 9 (56.3) 0.017 
Bacterial vaginosis   
     by Gram Staind 
     by Amsel’s criteria 
 
13 (59.1) 
7 (38.9) 
 
50 (76.9) 
16 (42.1) 
 
0.106 
0.819 
 
11 (84.6) 
4 (44.4) 
 
0.540 
1.00 
Pelvic Pain       
     Mean composite pain scoree (standard deviation) 58.0 (21.9) 72.3 (23.9) 0.014 75.2 (20.7) 0.658 
a C. trachomatis 
b p-value in comparison to the Mg+/Gc-/Ct- group 
c p-value in comparison to the Gc+/Mg-/Ct- 
d Normal or intermediate vs. BV flora 
e Mean composite pain score=(mean of current pelvic pain score, average pelvic pain score and worst pelvic pain 
score) X 10 
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Table 12. Clinical characteristics of women with M. genitalium (Mg) only, women with C. trachomatis (Ct) 
only, and women with M. genitalium and C. trachomatis 
 
Mg+/Ct-/Gc-a 
(N=22) 
n (%) 
Ct+/Mg-/Gc- 
(N=45) 
n (%) 
p-valueb Ct+/Mg+/Gc- 
(N=9) 
n (%) 
p-valuec
 
Presenting Complaints      
     Nausea/vomiting   
     Non-menstrual vaginal bleeding 
     Heavier menstrual bleeding 
     Bleeding during or after sex 
     Abnormal vaginal discharge 
     More frequent urination  
10 (45.5) 
9 (40.9) 
10 (45.5) 
4 (18.2) 
14 (63.6) 
11 (50.0) 
21 (46.7) 
26 (57.8) 
17 (37.8) 
12 (26.7) 
32 (71.1) 
21 (46.7) 
0.926 
0.194 
0.547 
0.444 
0.536 
0.798 
4  (44.4) 
4 (44.4) 
1 (11.1) 
1 (11.1) 
7 (77.8) 
5 (55.6) 
1.00 
0.489 
0.244 
0.428 
0.684 
0.626 
Markers of Inflammation      
     Elevated temperature ( >38.3o C) 
     Elevated white blood cell count ( >10,000 mm3 ) 
     Erythrocyte Sedimentation Rate ( >15 mm/hr) 
     C-Reactive Protein ( >5mg/dL) 
     Bilateral adnexal tenderness 
0 (0.0) 
4 (28.6) 
5 (22.7) 
1 (4.5) 
17 (77.3) 
0 (0.0) 
9 (22.5) 
19 (42.2) 
6 (13.3) 
35 (77.8) 
--- 
0.722 
0.118 
0.269 
0.963 
1 (14.3) 
2 (22.2) 
6 (66.7) 
3 (33.3) 
7 (77.8) 
0.137 
0.986 
0.179 
0.161 
1.00 
Mucopurulent cervicitis 9 (47.4) 22 (52.4) 0.717 6 (66.7) 0.434 
Bacterial vaginosis  
     by Gram Staind 
 
13 (59.1) 
 
28 (65.1) 
 
0.634 
 
4 (50.0) 
 
0.450 
     by Amsel’s criteria 7 (38.9) 15 (46.9) 0.585 2 (33.3) 0.672 
Pelvic Pain  
     Mean composite pain scoree (standard deviation) 
 
58.0 (21.9) 
 
61.8 (22.9) 
 
0.517 
 
64.4 (26.8) 
 
0.764 
a N. gonorrhoeae 
b p-value in comparison to the Mg+ /Ct-/Gc- group 
c p-value in comparison to the Ct+/Mg-/Gc- 
d Normal or intermediate vs. BV flora 
e Mean composite pain score=(mean of current pelvic pain score, average pelvic pain score and worst pelvic pain 
score) X 10 
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3.1 ABSTRACT 
Objective: Mycoplasma genitalium has been identified as a cause of pelvic inflammatory disease (PID), 
the inflammation of the female upper genital tract which may result in serious reproductive sequelae.  As 
the demographic, behavioral and sexual risk profile of women with M. genitalium is not well understood, 
we sought to describe the risk factors of M. genitalium among women presenting with clinically suspected 
PID. 
Methods: Data from 586 participants in the PID Evaluation and Clinical Health Study were analyzed.  
Demographic, sexual history, and behavioral characteristics, including age, race, marital status, education 
level, sexually activity, number of sexual partners, history of STDs, bacterial vaginosis and PID, 
contraception use, oral and anal sex, age at sexual debut, douching practices, and drug, alcohol and 
tobacco use, were compared between women testing positive and negative for M. genitalium as 
determined by polymerase chain reaction (PCR), and between M. genitalium positive women and 
Chlamydia trachomatis and/or Neisseria gonorrhoeae positive women.  As the profiles of women with 
cervical M. genitalium were similar to women with endometrial M. genitalium, comparisons using 
combined cervical and/or endometrial M. genitalium results are presented.   
Results: Being younger than 25 years of age (OR 2.3, 95% CI 1.3-4.1), douching 2 or more times per 
month (OR 1.9, 95% CI 1.2-3.3), and smoking cigarettes (OR 1.9, 95% CI 1.2-3.1) were significantly 
associated with M. genitalium.  After adjusting for C. trachomatis and/or N. gonorrhoeae infection, age 
(OR 3.5, 95% CI 1.6-8.1) and douching (OR 2.1, 95% CI 1.1-4.2) were significantly associated with M. 
genitalium infection.   Women with M. genitalium only were significantly less likely to be African-
American (59.1% vs. 86.0%, p=0.001) than women with N. gonorrhoeae and/or C. trachomatis. 
Conclusion: PID patients who tested positive for M. genitalium had some characteristics that are 
commonly associated with other STDs and PID.  The demographic, sexual and behavioral characteristics 
of M. genitalium positive women were generally similar to women with chlamydial and/or gonococcal-
PID. 
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3.2 INTRODUCTION 
Pelvic inflammatory disease (PID) is the inflammation of the female upper genital tract caused by 
ascension of organisms from the lower genital tract.  PID is a polymicrobial condition and in many 
studies only 30% to 50% of PID cases have been associated  with the sexually transmitted pathogens 
Chlamydia trachomatis and Neisseria gonorrhoeae (79, 159, 160).   Bacterial vaginosis-associated 
anaerobes (161) and Mycoplasma genitalium (42) have also been identified as an etiologic agents of PID.  
Since serious sequelae, including recurrent PID, tubal factor infertility (TFI), ectopic pregnancy and 
chronic pelvic pain frequently follow an episode of PID (158), it is important to identify risk factors 
associated with the pathogens that can cause PID.  An understanding of modifiable risk factors may aid in 
efforts to reduce the risk of infection and subsequent serious sequelae. 
Evidence suggests that M. genitalium may be sexually transmitted.  First, it has been associated 
with a history of sexual intercourse (21, 22).  Second, the concordance rates among female sexual 
partners of M. genitalium infected males have been high, ranging from 45% to 71% (23, 33, 96, 162).   
Third, in a study of 19 couples conducted by Hjorth et al, sequence-based typing of M. genitalium 
revealed sexual transmission, for the sequence type found in specimens from the female partner was 
identical to that found in the male partner in all the couples studied (26). 
Given that data suggests M. genitalium may be sexually transmitted, the demographic, behavioral 
and sexual risk profile of women with M. genitalium should be similar to women with other bacterial 
sexually transmitted diseases (STDs).  However, few studies have examined the risk factors associated 
with M. genitalium infection.  Therefore, we sought to describe the demographic, sexual health and 
behavioral risk factors of genital tract M. genitalium infection identified by polymerase chain reaction 
(PCR) in a population of women presenting with clinically suspected PID. We hypothesize that women 
with M. genitalium will be more likely to exhibit characteristics associated with other bacterial STDs, 
such as younger age (59), black race (60-62), history of STDs or PID, young age at sexual debut (47, 48), 
rare or inconsistent condom use (67), hormonal contraceptive use (66), douching (51-54), and drug, 
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tobacco or alcohol use (55, 65) than women without M. genitalium.  We also hypothesize that the risk 
factors for M. genitalium will be similar to risk factors of C. trachomatis and N. gonorrhoeae.   
 
3.3 METHODS 
3.3.1 Study Population 
Data from the baseline interview of the PID Evaluation and Clinical Health (PEACH) Study, described in 
detail elsewhere (169), were analyzed.  The PEACH Study evaluated the effectiveness of inpatient versus 
outpatient treatment for PID in preventing infertility.  Between March 1996 and February 1999, non-
pregnant women between the ages of 14 and 36 years were recruited from emergency departments and 
outpatient facilities (OB/GYN clinics, sexually transmitted disease clinics, and private practices) from 
seven primary (Atlanta, GA; Birmingham, AL; Charleston, SC; Detroit, MI; Philadelphia, PA; Pittsburgh, 
PA; and Providence, RI) and six secondary sites in the U.S..  Institutional Review Board approval was 
obtained from each site.  Women were eligible to participate if they had clinically suspected PID as 
defined by: 1) complaints of acute pelvic pain (<30 days); 2) a clinical finding of pelvic tenderness; and 
3) evidence of lower genital tract inflammation.  Women were excluded from the study if they had severe 
disease requiring inpatient management, could not tolerate an outpatient regimen due to vomiting, had an 
allergy to antibiotics, experienced a delivery, abortion or gynecologic surgery within the past 45 days, had 
a prior hysterectomy, bilateral salpingectomy, or bilateral tubal ligation, had a tubo-ovarian abscess 
documented by ultrasound or laparoscope and/or had appendicitis, hemorrhagic ovarian cyst or other 
condition requiring surgery by ultrasound or laparoscopy.  Eight hundred thirty one women were enrolled 
into the PEACH Study.  For this analysis, stored cervical and endometrial specimens were tested for M. 
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genitalium as part of a subsequent ancillary study to PEACH, which has been described in detail 
elsewhere (42).  M. genitalium PCR assays were available on a subset of 586 women. 
3.3.2 Data Collection  
Baseline data were collected by trained research staff at each study center using standardized interview, 
examination, and specimen collection techniques. Information was collected on demographic 
characteristics, medical, gynecologic and sexual histories, presenting complaints, substance use, current 
medications and contraception. Cervical and vaginal swabs, endometrial biopsies, and serum and urine 
samples were obtained from participants. 
3.3.3 Detection of M. genitalium 
Previously collected cervical and endometrial samples stored at -70°C were tested for M. genitalium using 
the MgPa-IMW PCR assay targeting the MgPa gene (170).  This assay has an analytical sensitivity of 15 
genomes (170) and a high clinical sensitivity and specificity relative to TMA, another M. genitalium 
NAAT assay (28).  For all samples testing positive, a repeat MgPa PCR assay was performed using 
another aliquot of the sample to rule out PCR product contamination or cross-contamination.  All samples 
initially positive were verified as positive in this confirmatory test.  
3.3.4 Detection of N. gonorrhoeae and C. trachomatis  
Previously collected and stored baseline cervical and endometrial samples were assessed for N. 
gonorrhoeae by culture and C. trachomatis by PCR at a central laboratory, as previously described (79).   
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3.3.5 Risk Factors 
The following are the baseline variables that we evaluated as potential risk factors for M. genitalium 
infection: age, race, marital status, level of education, sexual activity, number of lifetime sexual partners, 
new sexual partner in the past 4 weeks, history of STDs, history of BV, history of PID, hormonal 
contraceptive use, condom use, oral sex, anal sex, age at sexual debut, vaginal douching practices, and 
drug, alcohol use, and tobacco use. 
3.3.6 Statistical Methods 
The Chi-square and Fischer’s exact tests were used to evaluate the risk profile of M. genitalium infection.  
Women with M. genitalium only were compared to: 1) women without M. genitalium; and 2) women with 
N. gonorrhoeae and/or C. trachomatis.  Cervical and endometrial results were considered in separate and 
combined analyses.   
The associations between M. genitalium genital tract infection and potential risk factors were 
assessed with univariate and multivariate logistic regression models.  Variables for which the p-value was 
less than 0.20 in univariate analysis were considered for multivariable analysis. We used multivariate 
logistic models to quantify the risk of having M. genitalium for the various risk factors while controlling 
for other risk factors simultaneously.  If multi-collinearity existed among some covariates being 
considered for model inclusion, one of the collinear variables was removed.  The result of such removal is 
typically to reduce the variance in the model without introducing bias into the model estimates, since the 
deleted variable contains redundant information.  The decision regarding which variable to remove was 
made on the basis of biological plausibility and strength of association.  The model was rerun adjusting 
for C. trachomatis and/or N. gonorrhoeae infection.  All data were analyzed using SAS version 9.2 for 
windows. 
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3.4 RESULTS 
Table 13 provides the baseline demographic, sexual health and behavioral characteristics of study 
participants according to M. genitalium PCR result.  As risk factors for lower and upper genital tract M. 
genitalium infection were generally similar, only risk factors for combined cervical and/or endometrial M. 
genitalium are presented.  Approximately 15% (88/586) of the study participants tested positive for M. 
genitalium in the cervix and/or endometrium.  Being younger than 25 years of age (OR 2.3, 95% CI 1.3-
4.1), douching 2 or more times per month (OR 1.9, 95% CI 1.2-3.3), and smoking cigarettes (OR 1.9, 
95% CI 1.2-3.1) were significantly associated with M. genitalium infection.  There were non-significant 
trends towards associations between M. genitalium and African-American race (OR 1.4, 95% CI 0.8-2.5), 
sexual activity (OR 1.6, 95% CI 0.8-3.1), history of BV (OR 0.6, 95% CI 0.3-1.0), rare/occasional 
condom use (OR 1.4, 95% CI 0.8-2.6), and illicit drug use (OR 1.7, 95% CI 1.0-2.7). 
In the multivariate model, being less than 25 years old (AOR 2.8, 95% CI 1.5-5.2) and douching 
2 or more times in the previous month (AOR 2.3, 95% CI 1.3-4.0) and smoking  (AOR 2.0, 95% CI 1.2-
3.3).  were independently associated with M. genitalium infection (Table 14).  After adjusting for C. 
trachomatis and/or N. gonorrhoeae infection, age (AOR 3.6, 95% CI 1.6-8.1) and douching (AOR  2.1, 
95% CI 1.1-4.0) were significantly associated with M. genitalium infection, while the trend towards 
association between smoking and M. genitalium remained (AOR 1.9, 95% CI 1.0-3.4), but was no longer 
significant. 
Among women who tested positive for M. genitalium, 22 women did not test positive for N. 
gonorrhoeae or C. trachomatis.  The demographic, sexual health and behavioral characteristics between 
women with and without M. genitalium were generally no different when analyzed in this subset of 
women without N. gonorrhoeae or C. trachomatis (Table 15).  Power may have been limited due to the 
small number of participants in this subgroup analysis.   
 The baseline characteristics of women testing positive for M. genitalium only were generally 
similar to women with N. gonorrhoeae and/or C. trachomatis identified in cervical and/or endometrial 
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specimens.  Women with M. genitalium only were significantly less likely to be African-American 
(59.1% vs. 86.0%, p=0.001) than women with N. gonorrhoeae and/or C. trachomatis (Table 16).  
However, this was the only characteristic that differed between these two groups. 
3.5 DISCUSSION 
In our study population of women with mild to moderate clinically suspected PID, compared to women 
who tested negative for M. genitalium, women who tested positive for M. genitalium in the cervix and/or 
endometrium were more likely to have some characteristics and behaviors that are commonly associated 
with other STDs and PID, including young age, smoking, and vaginal douching.   Further, after adjusting 
for N. gonorrhoeae and/or C trachomatis co-infection, women with M. genitalium were significantly 
more likely to be less than 25 years of age and douche than women without M. genitalium, while the trend 
towards association between smoking and M. genitalium remained but did not reach significance.   
Biologically, younger females are more susceptible to bacterial infections than older females due 
to cervical ectopy.  During adolescence, endocervical columnar epithelial cells extend to the vaginal 
surface, increasing the surface area and increasing the number of receptive cells which may favor the 
growth of some mucosal pathogens (59), including M. genitalium.  Younger women may also be at a 
greater risk for M. genitalium because they may be more likely to engage in risky sexual behaviors, such 
as unprotected intercourse and multiple sexual partners, or have less immunity.  Douching can create an 
environment favorable to facultative aerobes and anaerobes over the usually predominant hydrogen-
peroxide-producing lactobacilli (63).  Douching can alter the vaginal microflora, remove protective 
components from the vagina or cervix, and/or promote the ascension of microorganisms from the lower to 
the upper genital tract, all increasing a woman’s susceptibility to infection (64).  Smoking is thought to 
exert a biologic effect on the genital tract via compromised immunity or altered estrogen status (55, 65), 
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and has been positively associated with PID (55).  Further, smoking may mark poor health-seeking 
behaviors.   
To our knowledge, this is the first study to compare the risk factors associated with M. genitalium 
lower and/or upper female genital tract infection to women with other bacterial STDs.  As we 
hypothesized, the characteristics of M. genitalium were similar to those of other sexually transmitted 
bacteria, N. gonorrhoeae and C. trachomatis.  The only characteristic that differed between the two 
groups of women was race.  Only one published study has looked at the risk factors among women with 
M. genitalium upper genital tract infection (41).  Cohen et al used PCR to analyze cervical, endometrial, 
and fallopian tube samples from 123 women presenting at an STD clinic with laparoscopically confirmed 
salpingitis (41).  Age, marital status and median number of sexual partners were not associated with M. 
genitalium infection at any site, while being HIV positive was independently associated with infection 
(Adjusted Hazard Ratio (AHR) 2.2, 95% CI 1.2-3.7) (41).  However, the analyses included women with 
gonorrhea or chlamydial infections, which may have biased the results.   
In our study, M. genitalium infection was not associated with all traditional markers of STDs, 
including sexual activity, number of sexual partners, new sexual partner, history of STDs or PID, 
hormonal contraception and condom use, oral and anal sex, and age at sexual debut.  Our findings are not 
consistent with other studies that have examined the risk factors for M. genitalium infection (14, 22, 68).  
Manhart et al used data from a subsample of  participants aged 18 to 27 years in Wave III of the National 
Longitudinal Study of Adolescent Health (Add Health) to examine the potential risk factors of M. 
genitalium (22).  PCR was used to test the urine of 1714 women and 1218 men for M. genitalium (22).  
M. genitalium infection was strongly associated with ever having engaged in vaginal intercourse 
(Prevalence Ratio (PR) 22.5, 95% CI 4.3-116.6), and in multivariate analyses the prevalence of M. 
genitalium increased by 10% with each additional vaginal intercourse partner in the past year (PR 1.1 per 
partner in the past year, 95% CI 1.0-1.2) (22).  Further, M. genitalium was more prevalent in individuals 
that ever lived with a sexual partner (PR 11.2, 95% CI 3.2-39.5) and in individuals who reported condom 
use during last sexual intercourse (PR 3.9, 95% CI 1.3-11.5) (22).   Huppert et al tested vaginal swabs 
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from 331 sexually active female adolescents aged 14 to 21 years recruited from inner-city medical center 
for M. genitalium using PCR (68).  Sexual intercourse within the last 7 days was associated with a 2-fold 
increase in the odds of M. genitalium infection (OR 2.0, 95% CI 1.1-3.2), after adjusting for C. 
trachomatis (68).  Tosh et al used PCR to test vaginal samples from 383 female adolescents aged 14-17 
years enrolled in urban primary health care clinics in the U.S. (14).  With the exception of one individual, 
M. genitalium was identified exclusively among individuals reporting history of vaginal intercourse and 
having a recent sexual partner (OR 1.4, 95% CI 1.2-1.7) was independently associated with M. genitalium 
(14).  Our study is unique in that we examined the risk factors of lower and/or upper genital tract M. 
genitalium infection.  However, all women enrolled in the PEACH study had clinically suspected PID and 
they may have had homogeneity of risk behaviors, resulting in our null findings.  Further, in the PEACH 
study, M. genitalium infection was associated with C. trachomatis and/or N. gonorrhoeae co-infection 
(42), which may have biased our results.  In fact, approximately two-thirds (43/63, 66.2%) of women who 
tested positive for M. genitalium in the cervix and/or endometrium were also infected with N. 
gonorrhoeae and/or C trachomatis in the cervix and/or endometrium (42).  Still, after excluding women 
with co-infections, M. genitalium was not significantly associated with these known STD risk factors.  
However, due to the small number of participants in this subgroup analysis, power may have been 
limited. 
We previously reported that among PEACH participants, women testing positive for M. 
genitalium tended to be less symptomatic than women testing positive for N. gonorrhoeae (175).  
Compared to women with gonococcal PID, women with M. genitalium were less likely to present with 
elevated systemic inflammatory markers, an elevated vaginal pH, and mucopurulent cervicitis and had 
lower pelvic pain scores.  Several other PCR studies have failed to find a strong association between 
symptoms and M. genitalium lower genital tract infection (14, 22, 32).  If M. genitalium is indeed 
sexually transmitted, a high number of unrecognized infected individuals may provide the reservoir for 
spreading M. genitalium to others via sexual activity.  Further, asymptomatic individuals may not seek 
treatment for lower genital tract infections, increasing the risk of developing PID and PID-associated 
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sequelae.  Future studies should explore factors associated with asymptomatic M. genitalium infections in 
the general population.  The identification of correlates associated with M. genitalium will help to identify 
women at risk for disease acquisition.  This may help direct screening programs and ultimately prevent 
serious reproductive and gynecologic morbidities, including PID and its associated sequelae. 
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3.6 TABLES 
Table 13. Characteristics of study participants and association with M. genitalium cervical and/or 
endometrial infection 
 
 
 
Characteristic 
M. genitalium 
positive 
N=88 
n (%)1 
M. genitalium 
negative 
N=498 
n (%)2 
 
 
 
OR (95% CI) 
Demographic    
Age  
     < 25 years 
 
71 (18.2) 
 
319 (81.8) 
 
2.3 (1.3-4.1) 
     > 25 years 
 
Race/Ethnicity 
17 (8.7) 179 (91.3)  
     African-American  
     White/Hispanic/Other 
69 (16.2) 
19 (11.9) 
358 (83.8) 
140 (99.1) 
1.4 (0.8-2.4) 
 
Marital Status 
   
     Unmarried 71 (14.7) 411 (85.3) 1.4 (0.6-3.1) 
     Married 
 
Education 
7 (11.3) 55 (88.7)  
     < High school  
     > High school 
38 (16.7) 
50 (13.9) 
189 (83.3) 
308 (86.0) 
1.2 (0.8-2.0) 
Sexual  Health    
Sexually active     
     Yes 
     No 
 
78 (15.8) 
10 (10.7) 
415 (84.2) 
83 (89.2) 
1.6 (0.8-3.1) 
≥ 2 sexual partners     
     Yes 
     No 
 
10 (17.9) 
78 (14.7) 
46 (82.1) 
452 (85.3) 
1.3 (0.6-2.6) 
New sexual partner in last month    
     Yes 
     No 
10 (17.5) 
78 (14.7) 
47 (82.5) 
451 (85.3) 
1.2 (0.6-2.5) 
History of STD3    
     Yes 
     No 
 
52 (15.0) 
35 (15.0) 
295 (85.0) 
198 (85.0) 
1.0 (0.6-1.6) 
History of BV    
     Yes 
     No 
 
13 (10.0) 
73 (16.7) 
117 (90.0) 
365 (83.3) 
0.6 (0.3-1.0) 
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Table 13 continued 
 
History of PID    
     Yes 
     No 
23 (12.9) 
64 (15.9) 
155 (87.1) 
338(84.1) 
0.8 (0.5-1.3) 
 
Rare/occasional condom use4 
   
     Yes 
     No 
 
60 (17.2) 
18 (12.5) 
289 (82.8) 
126 (87.5) 
1.4 (0.8-2.6) 
Consistent condom use5    
     Yes 
     No 
 
7 (10.9) 
71 (16.5) 
57 (89.1) 
358 (83.5) 
1.2 (0.5-2.7) 
Oral sex    
     Yes 
     No 
 
23 (17.6) 
63 (15.0) 
108 (82.4) 
356 (85.0) 
1.2 (0.7-2.0) 
Anal sex    
     Yes 
     No 
 
4 (21.1) 
84 (14.8) 
15 (78.9) 
483 (85.2) 
1.5 (0.5-4.7) 
Age at sexual debut  
     < 15 years 
     > 15 years 
 
48 (15.8) 
40 (14.1) 
 
255 (84.2) 
243 (85.9) 
 
1.1 (0.7-1.8) 
Behavioral    
Vaginal douche > 2 times in past month     
     Yes 
     No 
 
26 (22.8) 
62 (13.1) 
88 (77.8) 
410 (86.9) 
1.9 (1.2-3.3) 
Illicit drug use     
     Yes 
     No 
 
32 (20.4) 
56 (13.1) 
125 (79.6) 
370 (86.9) 
1.7 (1.0-2.7) 
Current smoker    
     Yes 
     No 
 
49 (20.2) 
39 (11.5) 
194 (79.8) 
301 (88.5) 
1.9 (1.2-3.1) 
Alcohol use    
     Yes 
     No 
 
48 (14.8) 
40 (15.5) 
277 (85.2) 
218 (84.5) 
0.9 (0.6-1.5) 
Alcohol drinks per week 
     > 7 drinks 
     < 7 drinks 
 
13 (19.1) 
75 (14.6) 
 
55 (80.9) 
440 (85.4) 
 
1.4 (0.7-2.7) 
 
* Missing observations: marital status, n=42; education, n=1; history of STD, n=6; history of BV, n=18; history of 
PID, n=6; hormonal contraception use, n=93; condom use, n=93; oral sex, n=36; drug use, n=3; smoking, n=3, 
alcohol use, n=3. 
 
1 % of total study population with characteristic that tested positive for M. genitalium 
2 % of total study population with characteristic that tested negative for M. genitalium 
3 History of N. gonorrhoeae, C. trachomatis, or Trichonomas vaginalis 
4 Condoms used 0 to 5 out of 10 sexual encounters 
5 Condoms used 10 out of 10 sexual encounters 
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Table 14. Multivariate model of cervical and/or endometrial M. genitalium infection 
 
Characteristic AOR (95% CI) AOR1 (95% CI) 
Demographic 
Age  < 25 years 
Black race 
 
2.8 (1.5-5.2) 
1.4 (0.8-2.6) 
 
3.6 (1.6-8.1) 
1.2 (0.6-2.4) 
Sexual Health 
History of BV 
Rare/occasional condom use2 
 
0.5 (0.2-1.0) 
1.4 (0.8-2.6) 
 
0.5 (0.2-1.2) 
1.1 (0.6-2.2) 
Behavioral 
Vaginal douche > 2 times in past month 
Smoking 
 
2.3 (1.3-4.1) 
2.0 (1.2-3.3) 
 
2.1 (1.1-4.0) 
1.9 (1.0-3.4) 
1 Additionally adjusted for C. trachomatis and/or N. gonorrhoeae co-infection 
2 Condoms used 0 to 5 out of 10 sexual encounters 
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 Table 15.  Characteristics of study participants and association with M. genitalium cervical and/or 
endometrial infection among women without C. trachomatis or N. gonorrhoeae cervical and/or endometrial 
infection 
 
 
 
Characteristic 
M. genitalium 
positive 
N=22 
n (%)1 
M. genitalium 
negative 
N=263 
n (%)2 
 
 
 
OR (95% CI) 
Demographic    
Age  
     < 25 years 
 
17 (10.7) 
 
142 (89.3) 
 
2.9 (1.0-8.1) 
     > 25 years 
 
Race/Ethnicity 
5 (3.9) 121 (96.0)  
     African-American  
     White/Hispanic/Other 
13 (7.5) 
9 (8.0) 
160 (92.5) 
103 (92.0) 
0.9 (0.4-2.2) 
 
Marital Status 
   
     Unmarried 20 (8.6) 213 (91.4) 3.9 (0.5-30.2) 
     Married 
 
Education 
1 (2.3) 42 (97.7)  
     < High school  
     > High school 
7 (7.6) 
15 (7.8) 
85 (92.4) 
178 (92.2) 
1.0 (0.4-2.5) 
Sexual Health 
Sexually active  
   
     Yes 
     No 
 
19 (8.1) 
3 (6.0) 
216 (91.9) 
47 (94.0) 
1.4 (0.4-4.8) 
≥ 2 sexual partners     
     Yes 
     No 
 
3 (14.3) 
19 (7.2) 
18 (85.7) 
245 (92.8) 
2.1 (0.6-7.9) 
New sexual partner in past month    
     Yes 
     No 
 
4 (14.8) 
18 (7.0) 
23 (85.2) 
240 (93.0) 
2.3 (0.7-7.4) 
History of STD3    
     Yes 
     No 
 
12 (7.5) 
10 (8.3) 
147 (92.5) 
111 (91.7) 
0.9 (0.4-2.2) 
History of BV    
     Yes 
     No 
 
5 (6.6) 
17 (8.3) 
71 (93.4) 
187 (91.7) 
0.8 (0.3-2.1) 
History of PID    
     Yes 
     No 
 
7 (8.4) 
15 (7.5) 
76 (91.6) 
185 (92.5) 
1.1 (0.4-2.9) 
Hormonal contraception use    
     Yes 
     No 
4 (7.5) 
15 (8.2) 
49 (92.5) 
167 (91.8) 
0.9 (0.3-2.9) 
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Table 15 continued 
 
Rare/occasional condom use4    
     Yes 
     No 
 
15 (8.7) 
4 (6.4) 
158 (91.3) 
58 (93.6) 
1.4 (0.4-4.3) 
Consistent condom use5    
     Yes 
     No 
 
1 (3.2) 
18 (8.8) 
30 (96.8) 
186 (91.2) 
1.1 (0.2-5.1) 
Oral sex    
     Yes 
     No 
 
5 (8.2) 
16 (8.0) 
56 (91.8) 
185 (92.0) 
1.0 (0.4-2.9) 
Anal sex    
     Yes 
     No 
 
1 (16.7) 
21 (7.5) 
5 (83.3) 
258 (92.5) 
2.5 (0.3-2.6) 
Age at sexual debut 
     < 15 years 
     > 15 years 
 
11 (8.0) 
11 (7.4) 
 
126 (92.0) 
137 (92.6) 
 
1.1 (0.5-2.6) 
Behavioral 
Vaginal douche > 2 times in past month  
   
     Yes 
     No 
 
6 (13.0) 
16 (6.7) 
40 (87.0) 
223 (93.3) 
2.1 (0.8-5.7) 
Illicit drug use     
     Yes 
     No 
 
7 (11.1) 
15 (6.8) 
56 (88.9) 
205 (93.2) 
1.7 (0.7-4.4) 
Current smoker    
     Yes 
     No 
 
9 (8.1) 
13 (7.5) 
102 (91.9) 
160 (92.5) 
1.1 (0.4-2.6) 
Alcohol use    
     Yes 
     No 
 
14 (8.5) 
8 (6.7) 
151 (91.5) 
111 (93.3) 
1.3 (0.5-3.2) 
Alcohol drinks per week 
     > 7 drinks 
     < 7 drinks 
 
4 (12.9) 
18 (7.1) 
 
27 (87.1) 
235 (92.9) 
 
1.9 (0.6-6.1) 
 
* Missing observations: marital status, n=9; history of STD, n=5; history of BV, n=5; history of PID, n=2; hormonal 
contraception use, n=50; condom use, n=50; oral sex, n=23; drug use, n=2; alcohol use, n=1. 
 
1 % of total study population with characteristic that tested positive for M. genitalium  
2 % of total study population with characteristic that tested negative for M. genitalium 
3 History of N. gonorrhoeae, C. trachomatis, or Trichonomas vaginalis 
4 Condoms used 0 to 5 out of 10 sexual encounters  
5 Condoms used 10 out of 10 sexual encounters 
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Table 16. Characteristics of women with M. genitalium only identified in the cervix and/or endometrium 
compared to women with N. gonorrhoeae and/or C. trachomatis in the cervix and/or endometrium 
 
 
 
Characteristic 
M. genitalium 
positive 
n=22 
n (%) 
N. gonorrhoeae and/or  
C. trachomatis positive 
n=172 
n (%) 
 
 
 
p-value 
Demographic    
Age < 25 years 17 (77.3) 132 (76.7) 0.96 
 
African-American race/ethnicity 
 
13 (59.1) 
 
148 (86.0) 
 
0.001 
    
Unmarried 20 (95.2) 151 (95.0) 1.00 
    
< High school education 7 (31.8) 82 (47.7) 0.16 
Sexual  History    
Sexually active 19 (86.4) 146 (84.9) 0.85 
    
≥ 2 sexual partners  3 (13.6) 24 (13.9) 1.00 
    
New sexual partner in past month 4 (18.2) 17 (9.9) 0.27 
    
History of STD1 12 (54.4) 108 (62.8) 0.45 
    
History of N. gonorrhoeae or C. trachomatis 11 (50.0) 92 (54.4) 0.69 
    
History of BV 5 (22.7) 32 (19.0) 0.68 
    
History of PID 7 (31.8) 50 (29.2) 0.80 
    
Hormonal contraception use 4 (21.0) 30 (20.5) 1.00 
    
Rare/occasional condom use2 15 (78.9) 101 (69.2) 0.38 
    
Consistent condom use3 1 (5.3) 19 (13.0) 0.47 
    
Oral sex 5 (23.8) 32 (19.5) 0.58 
    
Anal sex 1 (4.5) 7 (4.07) 1.00 
    
Age at sexual debut <15 years 11 (50.0) 94 (54.6) 0.68 
Behavioral    
Vaginal douche >2 times in past month 6 (27.3) 4 (24.4) 0.77 
    
Illicit drug use 7 (31.8) 50 (29.1) 0.79 
    
Current smoker 9 (40.9) 74 (43.2) 0.85 
    
Alcohol use 14 (63.6) 98 (57.0) 0.55 
    
Alcohol use, > 7 drinks/week 4 (18.2) 24 (13.9) 0.53 
1 History of N. gonorrhoeae, C. trachomatis, or Trichonomas vaginalis 
2 Condoms used 0 to 5 out of 10 sexual encounters 
3 Condoms used 10 out of 10 sexual encounters 
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4.1 ABSTRACT 
Objectives: Spontaneous abortion (SAB), the loss of a conceptus prior to 20 weeks, is the most common 
adverse outcome of pregnancy.  As genital tract infections may cause SABs and the prevalence and 
consequences of the sexually transmitted pathogen Mycoplasma genitalium in pregnant women is 
unknown, we sought to examine the relationship between prenatal M. genitalium infection and SAB. 
Methods: We conducted a nested case-control study among predominately young, African-American 
pregnant women recruited from an urban emergency department.  M. genitalium was measured by 
polymerase chain reaction (PCR) in urine collected at enrollment from 82 women who subsequently 
experienced a SAB and 134 control women who maintained their pregnancies past 22 weeks gestation.  
Clinical, demographic and behavioral characteristics of cases and controls were compared.  The 
relationship between M. genitalium and subsequent SAB was evaluated, adjusting for age, smoking, 
Chlamydia trachomatis infection, and previous SAB.   
Results: The prevalence of M. genitalium at enrollment was only slightly less than that of C. trachomatis 
(5.6% vs. 6.9%).  Compared to women testing negative for M. genitalium, M. genitalium positive women 
were more likely to report a history of other STDs (100% vs. 59.6%, p=0.008).  After adjusting for C. 
trachomatis PCR, M. genitalium was associated with nulliparity (AOR 3.4, 95% CI, 1.0-11.6), history of 
pelvic inflammatory disease (PID) (AOR 3.9, 95% CI 0.9-16.1), prior C. trachomatis infection (AOR 3.0, 
95% CI 0.8-10.5) and problems getting pregnant (AOR 4.8, 95% CI 0.9-25.7), although not all 
relationships were statistically significant.  Neither M. genitalium (AOR 0.6, 95% CI 0.1-2.3) nor C. 
trachomatis (AOR 0.4 95% CI 0.1-1.6) were independently associated with SAB.  Results did not differ 
after excluding women with vaginal bleeding at enrollment (M. genitalium OR 0.4, 95% CI 0.1-3.8; C. 
trachomatis OR 1.2, 95% CI 0.3-5.1). 
Conclusions:  Out study suggests that pregnant women with positive urine PCR for M. genitalium do not 
have an increased risk of SAB, but report a history of gynecologic and reproductive morbidities, 
including other STDs and PID.   
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 4.2 INTRODUCTION 
Spontaneous abortion (SAB), the loss of a conceptus prior to 20 weeks, is the most common adverse 
outcome of pregnancy, occurring in an estimated 15% of clinically recognized pregnancies (117) and up 
to 50% of all pregnancies (118).  Many SABs occurring in the first trimester are due to phenotypic and/or 
chromosomal abnormalities, while environmental factors may have a greater impact on SABs occurring 
in later pregnancy (118).  Evidence suggests that sexually transmitted bacterial and viral infections play a 
role in adverse pregnancy outcomes.  Syphilis, an infection caused by the spirochaete Treponema 
pallidum, is a recognized cause of SAB (176, 177).  Bacterial vaginosis (BV) in early pregnancy has been 
associated with a 2 to 5 fold increased risk of subsequent SAB (99, 128, 144-148), but others studies have 
not supported this association (120, 140-143).  The association between Chlamydia trachomatis and SAB 
has not been consistently reported. 
Mycoplasma genitalium, a sexually transmitted bacterium, has been linked to various adverse 
gynecologic and reproductive events.  It has been implicated as an etiological agent of cervicitis (33, 34, 
37, 69) and pelvic inflammatory disease (PID) (40, 42, 43, 104), independent of C. trachomatis and 
Neisseria gonorrhoeae.  Further, M. genitalium has been detected in cervical and salpingeal samples from 
women with laparoscopically confirmed salpingitis (41) and in cervical and endometrial specimens from 
women with histologically confirmed endometritis (108, 178).  A serologic relationship between M. 
genitalium and tubal factor infertility has also been identified (113, 114).   
Because M. genitalium has been associated with these morbidities, it is plausible that M. 
genitalium can infect the upper genital tract during pregnancy, resulting in adverse pregnancy outcomes.  
Data on M. genitalium in pregnancy are sparse, although a handful of studies among low-risk women 
have reported no relationship between M. genitalium and SAB (99, 116).  We conducted a nested case-
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control study to examine the role of M. genitalium in early pregnancy and subsequent SAB among 
predominantly young, single, African-American women with a history of STDs. 
 
4.3 METHODS 
4.3.1 Study Population 
For our analyses, data from participants enrolled in the prospective Early Pregnancy Study (EPS), 
designed to examine the influence of violence on SAB risk, were used.  During the period of January 
1999 through August 2001, adolescent girls and women aged 14 to 40 years who presented to the 
emergency department (ED) of the Hospital of the University of Pennsylvania and who resided in 
selected Philadelphia zip codes were screened for eligibility.   Nurse interviewers administered a brief 
screening questionnaire to identify all pregnant women less than 22 weeks gestation seen in the ED 
regardless of the reason for the visit.  Among the 1,249 pregnant adolescent and adult women who were 
eligible for the study, 96% agreed to participate (n =1,199).   The mean gestational age at enrollment was 
10.3 weeks.  All participants provided written informed consent, and the protocol and consent forms were 
approved by the institutional review board of the University of Pennsylvania.  
4.3.2 Data Collection  
At enrollment, nurse interviewers administered an in-person questionnaire.  The interview contained 
information regarding medical and reproductive history, sociodemographic factors, current level of social 
support, living arrangements, and complications of the pregnancy.  Hair samples were collected to 
measure cocaine use, and urine samples were collected to assess recent tobacco and alcohol use. Follow-
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up telephone interviews were conducted at 16 and 22 weeks of gestation to determine pregnancy status 
and to collect additional information.  Medical record reviews were conducted to confirm pregnancy 
outcome, which was obtained for 93% of participants. The 807 women who remained pregnant through 
22 weeks of gestation were classified as controls (67%), and the 392 women who experienced a non-
induced pregnancy loss before 22 weeks of gestation were classified as cases (33%).  Of the cases, 212 
experienced a SAB at enrollment and 180 experienced a SAB during the follow-up period.  For our 
subsequent EPS sub-analyses, women who were experiencing a SAB at enrollment and women who did 
not have a urine sample available for analysis were excluded.  The total sample for this sub-analysis was 
82 cases and 132 controls. 
4.3.3 Detection of M. genitalium and C. trachomatis 
Previously collected urine samples stored at -70°C were tested for M. genitalium and C. trachomatis.  M. 
genitalium was tested for using a PCR with primers deduced from the 16 S rRNA gene sequence of M. 
genitalium (179).  All positive results were confirmed by a second PCR amplifying a part of the M. 
genitalium MgPa adhesion gene with primers MgPa-1 and MgPa-3 as previously described (179, 180).  
The methods for the PCR detection of M. genitalium in urine have been previously validated (181).  C. 
trachomatis DNA was detected in the urine samples by amplification of a sequence of the cryptic plasmid 
using primers CP24 (5′GGG ATT CCT GTA ACA ACA AGT CAG G) and CP27 (5′CCT CTT CCC 
CAG AAC AAT AAG AAC AC) (182).  Positive results were confirmed with an inhibitor-controlled 
PCR detecting the 16S rRNA gene of chlamydia species modified from Pollard et al (183, 184).   
4.3.4 Microbiologic, demographic, current pregnancy and reproductive health history variables  
The following is a list of microbiologic, demographic, current pregnancy, and reproductive health history 
variables that were compared between SAB cases and pregnant controls: M. genitalium and C. 
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trachomatis infection detected by PCR, age, race, level of education, marital status, recipient of 
government assistance, gestational age at enrollment, vaginal bleeding during pregnancy, N. gonorrhoeae 
or BV infection during pregnancy, parity, history of STDs, history of PID, history of problems getting 
pregnant, history of prior SAB, prior ectopic pregnancies and alcohol, cigarette, marijuana and 
crack/cocaine use during current pregnancy.  All variables were self-reported during the baseline 
interview.  Cocaine use was additionally measured in hair specimens as previously described (185).  
Gestational age was calculated on the basis of self-reported date of the last menstrual period.   
   
4.3.5 Statistical Methods 
The microbiologic, demographic, current pregnancy and reproductive health history characteristics among 
cases and controls were compared using t, chi-square, and Fisher’s exact tests for continuous and 
dichotomous variables as appropriate.  The same characteristics were compared among women who 
tested positive for M. genitalium and women who did not test positive for M. genitalium.   
 Logistic regression models were used to investigate the relationship between M. genitalium urine 
PCR and SAB.  Analyses were repeated controlling for age, history of SAB, smoking, and C. trachomatis 
PCR.  Regression models were repeated including only women without a history of SAB, as including the 
history of SAB variable in the model may bias the relationship toward the null if there is an association 
between M. genitalium and habitual SABs.  We also repeated our analyses categorizing SAB by 
gestational age (<11 weeks, >11 weeks), since gestational age of 11 weeks or greater at time of SAB can 
be used as a marker for pregnancies which are more likely to be chromosomally normal and other factors 
such as infectious agents are more likely to cause pregnancy loss (118).   Finally, we repeated our 
analyses excluding women who were experienced vaginal bleeding at enrollment, as these women may 
have already been experiencing a SAB and this may have compromised temporality. 
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4.4 RESULTS 
Among all study participants, 5.6% (12/216) tested positive for M. genitalium and 6.9% (15/216) tested 
positive for C. trachomatis at enrollment.  Only one woman (0.05%) was co-infected with both bacteria.  
Participants were predominantly less than 30 years old (82.2%), African-American (89.5%), not married 
(81.3%) and receiving government assistance at time of enrollment (59.4%).  Nearly one-quarter (23.4%) 
of the participants had cocaine detected in their hair sample and 35.3% smoked cigarettes while pregnant.   
Most women (81.3%) reported at least one live birth and a history of a prior STD (61.7%), while nearly a 
third of women had a history of at least one SAB (31.5%).  
Compared to control women, cases were significantly more likely to report vaginal bleeding both 
within 24 hours of the enrollment visit (57.3% vs. 21.8%, p<0.0001) and during any time during 
pregnancy (65.4% vs. 37.3%, p<0.0001) (Table 17).  Cases were also significantly more likely to report a 
previous SAB (40.2% vs. 26.1%, p=0.030) than controls.  These were the only characteristics that 
differed between cases and controls.  Neither M. genitalium (AOR 0.6, 95% CI 0.1-2.8) nor C. 
trachomatis (AOR 0.41 95% CI 0.1-1.6) were independently associated with SAB, after adjusting for age, 
history of SAB, and smoking during pregnancy (Table 18).  Results were similar after excluding women 
who experienced vaginal bleeding at enrollment (M. genitalium OR 0.4, 95% CI 0.1-3.8; C. trachomatis 
OR 1.2, 95% CI 0.3-5.1) (Table 19).  When history of SAB was removed from the multivariate model, 
neither M. genitalium nor C. trachomatis were associated with SAB.   
Nearly 28% (22/79) of the cases experienced a SAB at less than 11 weeks gestation.  Among 
these earlier cases, none tested positive for M. genitalium and 3% (1/33) tested positive for C. 
trachomatis.  Among the cases who experienced a SAB at 11 or greater weeks of gestation, 4.3% (2/46) 
tested positive for M. genitalium and 4.3% (2/46) tested positive for C. trachomatis. When stratifying by 
gestational age of pregnancy loss, neither M. genitalium nor C. trachomatis were associated with SAB 
(<11 weeks, C. trachomatis OR 0.5, 95% CI 0.1-4.0; >11 weeks M. genitalium OR 0.6, 95% CI 0.1-3.0, 
C. trachomatis OR 0.5, 95% CI 0.7-2.9) (Table 20).  
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Compared to women without M. genitalium, women with M. genitalium were significantly more 
likely to report nulliparity (OR 3.4, 95% CI 1.0-11.3), history of PID (OR 3.9, 95% CI 0.9-16.0), prior C. 
trachomatis infection (OR 3.0, 95% CI 0.9-10.6) and problems getting pregnant (OR 4.9, 95% CI 0.9-
25.9) (Table 21).   Although results were not statistically significant, trends remained after adjusting for 
C. trachomatis PCR (nulliparity AOR 3.4, 95% CI, 1.0-11.6; history of PID AOR 3.9, 95% CI 0.9-16.1; 
prior C. trachomatis infection AOR 3.0, 95% CI 0.8-10.5; problems getting pregnant AOR 4.8, 95% CI 
0.9-25.7) (Table 22).  After adjusting for age, nulliparous women  were still more likely to test positive 
for M. genitalium than women who did not report nulliparity, but the results did not reach significance 
(AOR 2.8, 95% CI 0.8-9.8) (results not shown).  
4.5 DISCUSSION 
The prevalence of M. genitalium in our study population (5.6%) was higher than reported in other studies 
of pregnant women (44, 97, 99).  The higher prevalence of M. genitalium we report here is not all that 
surprising, as women in our study population were probably at high risk for STDs in general, as they were 
predominantly young, single, African-American, of lower socioeconomic status (SES) and reported a 
history of STDs.  Still, we did not find a statistically significant relationship between M. genitalium in 
pregnancy and subsequent SAB.  Our null findings are consistent with those of two other studies of M. 
genitalium and SAB.  Oakeshott et al used PCR to test urine samples from 915 pregnant women 
presenting at prenatal care at less than 10 weeks gestation in general practice and family planning clinics 
in London (99).  Only 0.66% of the samples tested positive for M. genitalium (99).  Women who 
experienced a subsequent SAB were not more likely to test positive for M. genitalium compared to the 
women who did not experience a SAB (1% vs. 0.6%, p=NS) (99).  In a case-control study of 1,014 
recently pregnant women in Guinea-Bissau, M. genitalium detected by PCR in cervical samples collected 
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within 24 hours of a SAB or delivery of a term neonate was not associated with SAB (OR 0.61, 95% CI 
0.07-2.51) (116).    
Similar to M. genitalium, C. trachomatis was not associated with SAB in our study population.  
Results from previous studies assessing the relationship between C. trachomatis infections and SAB are 
inconclusive.  Several serology studies found the presence of antibodies to C. trachomatis in the sera of 
women who have experienced repeated pregnancy loss (134, 135), while other studies have failed to find 
a significant association between C. trachomatis antibodies and SAB (136-138).  However, given the 
method of diagnosis used in these studies, women could have a current infection which might be 
undetected by serology.  Nevertheless, few studies using DNA based methods of detection have been 
conducted to examine the relationship between C. trachomatis and SAB and results have been 
inconsistent.  Among women undergoing in vitro fertilization (IVF), Witkin et al found a strong 
correlation between endocervical C. trachomatis and SAB after embryo transfer (p=0.004) (132).  
Further, C. trachomatis was identified in more women who had SABs than women who had term 
deliveries (27.3% vs. 1.8%) (132).  As all women were asymptomatic, the authors concluded that an 
undetected C. trachomatis infection may be responsible for SAB after IVF and embryo transfer (132).  
Contrary to this, Sozio and Ness did not find a significant relationship between acute lower genital tract 
C. trachomatis infection and SAB in their nested case-control pilot study of 52 women who experienced a 
SAB and 59 control women who maintained their pregnancies (133).  3.8% (2/52) of cases and 8.5% 
(5/59) of control women tested positive for C. trachomatis in their urine by ligase chain reaction, and 
women who experienced a SAB were not significantly more likely to have C. trachomatis infection than 
controls (OR 1.8, 95% CI 0.3-10.7) (133).  Thus, the role of C. trachomatis in SAB remains unexplained.  
In our study, the clinical, demographic and behavioral characteristics of pregnant women who 
tested positive for M. genitalium in early pregnancy and women who did not were similar.  Our results are 
similar to those reported by Labbe et al, in which M. genitalium was not associated with any 
demographic, behavioral, clinical or laboratory characteristic, including age, age at sexual debut, number 
of sexual partners, previous pregnancies, syphilis, HIV serology, N. gonorrhoeae and T. vaginalis 
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(p>0.05 for all) (116).  Conversely, Oakshott et al found that M. genitalium was more common in 
pregnant women who were less than 20 years of age (p=0.002), black (p=0.034), single (p=0.017) and had 
lower SES (p=0.007).  Our findings were likely due to homogeneity of women, which may have biased 
our results toward the null. 
Although M. genitalium was not associated with SAB or demographic and behavioral 
characteristics in this study, M. genitalium was associated with a history of other gynecologic and 
reproductive morbidities, including history of PID, prior chlamydial infection and problems getting 
pregnant.  Women who tested positive for M. genitalium were also more likely to report nulliparity, 
which may indicate problems getting pregnant. Further, our results suggest an independent relationship 
between M. genitalium and these conditions, as the results remained the same even after adjusting for C. 
trachomatis PCR.  Our results are consistent with other studies that have identified M. genitalium as a 
possible etiologic agent of other adverse reproductive conditions, such as non-gonococcal/non-chlamydial 
PID (42, 43, 69, 108, 178) and PID-associated sequelae (42), including tubal factor infertility (113, 114).  
It may be that M. genitalium was not associated with SAB in our study population of pregnant women 
because women with M. genitalium are more likely to develop PID and sub-fertility and would therefore 
not be enrolled in a pregnancy related study.  Future prospectively designed studies should examine the 
long-term sequelae of M. genitalium infections among pregnant and non-pregnant women. 
There are a few limitations to recognize as part of this study.  First, the small sample sizes of 
some of our subgroups limited statistical power.  Second, the mean gestational age at enrollment was 
approximately 10 weeks, so earlier SABs would have been missed.  Third, only archived urine samples 
were available for M. genitalium testing in this sub-study, and this may have limited our analyses.  The 
optimal specimen type used for M. genitalium PCR is unknown and has not been thoroughly assessed.  
Jensen et al compared the efficacy of first void urine (FVU) with cervical and urethral swab specimens 
for detection of M. genitalium using the in-house inhibitor-controlled PCR assays used in our study and 
found that urine samples were the most sensitive (31).  More infections were detected using urine samples 
(88%) than cervical (71%) and urethral swab specimens (57%), and the urine specimen was significantly 
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more efficient than both the cervical (p=0.049) and the urethral swab specimen (p=0.0009) (31).  
However, for optimal sensitivity, urine should be supplemented with a cervical specimen (31).  In our 
study, cervical PCR may have increased the sensitivity and detected more M. genitalium positive women.  
However, cervical samples were not available for testing.  Therefore, the reported prevalence of M. 
genitalium in our study population may be an underestimate of the true prevalence in our study 
population.  The null relationship between M. genitalium urine PCR and SAB in our study may further be 
explained by the fact that some women did not have upper genital tract infection, but instead had only 
urinary or lower genital tract infection, insufficient to cause SAB.   
In conclusion, this study is one of only a few to examine the role of M. genitalium in early 
pregnancy and subsequent SAB.  Among this population of mostly young, single, African-American 
pregnant women, a positive urine PCR for M. genitalium or C. trachomatis did not predict SAB.  
However, trends between M. genitalium and a history of gynecologic and reproductive morbidities, 
including other STDs, PID, and problems getting pregnant were evident, even after adjusting for 
concurrent C. trachomatis infection. 
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4.6 TABLES 
Table 17. Characteristics of women who experienced a SAB and women who maintained their pregnancies 
past 22 weeks gestation 
 
 
 
 
Characteristic 
Women who 
experienced 
a SAB 
n=82 
n (%) 
Women who maintained 
their pregnancies 
n=134 
n (%) 
 
 
 
 
p-value 
Infection 
M. genitalium (n=12) 
C. trachomatis (n=15) 
M. genitalium and C. trachomatis (n=1) 
 
3 (3.7) 
3 (3.7) 
0 
 
9 (6.7) 
12 (9.0) 
1 (0.7) 
 
0.54 
0.17 
1.00 
Demographic    
Mean age (standard deviation) 24.8 (6.2) 23.9 (5.7) 0.33 
    
Age     
     14-19 years 17 (20.7) 28 (20.9) 0.98 
     20-29 years 50 (61.0) 83 (61.9)  
     30-40 years 15 (18.3) 23 (17.2)  
    
Race/Ethnicity    
     African-American 72 (88.9) 120 (89.6) 0.89 
     Other 9 (11.1) 14 (10.4)  
    
Marital Status    
     Single 68 (82.9) 107 (79.8) 0.57 
     Married 14 (17.1) 27 (20.2)  
    
Education    
     < High school 25 (30.5) 50 (37.3) 0.31 
     ≥ High school 
 
Receiving government assistance 
57 (69.5) 
 
31 (37.8) 
84 (62.7) 
 
58 (43.3) 
 
 
0.43 
Current Pregnancy History 
Mean gestational age1 (standard deviation) 
   
Vaginal bleeding at enrollment 
    
 
8.7 (3.2) 
 
47 (57.3) 
 
9.5 (3.4) 
 
29 (21.8) 
 
0.08 
 
<0.0001 
Vaginal bleeding since LMP 53 (65.4) 
 
50 (37.3) <0.0001 
Alcohol use 30 (36.6) 44 (32.8) 0.57 
 
Cigarette smoking 
 
31 (38.3) 
 
44 (32.8) 
 
0.42 
 
Marijuana use 
 
17 (21.0) 
 
25 (18.7) 
 
0.68 
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Table 17 continued 
 
Crack/cocaine use2 
 
16 (25.4) 
 
21 (22.8) 
 
0.71 
 
N. gonorrhoeae 
 
1 (1.2) 
 
0 
 
0.38 
 
Bacterial vaginosis 
 
3 (3.7) 
 
6 (4.5) 
 
1.00 
Reproductive health history 
Nulliparous 
 
 
14 (17.1) 
 
27 (20.1) 
 
0.58 
 
Prior SAB 34 (40.2) 
 
35 (26.1) 0.03 
Prior ectopic pregnancy 
 
History of STD3 
 
History of PID 
 
History of problems getting pregnant 
5 (7.3) 
 
48 (60.0) 
 
6 (7.4) 
 
5 (6.3) 
6 (5.6) 
 
82 (62.1) 
 
15 (11.3) 
 
6 (4.5) 
0.75 
 
0.76 
 
0.36 
 
0.75 
 
* Missing observations: race, n=1; vaginal bleeding, n=1; cigarette smoking, n=1; marijuana use, n=1; crack/cocaine 
use, n=61; N. gonorrhoeae, n=2; bacterial vaginosis, n=3; prior incompetent cervix, n=2; prior ectopic pregnancy, 
n=41; history of STD, n=5; history of PID, n=3; history of problems getting pregnant, n=2 
 
1 Gestational age at enrollment in weeks  
2 Detected in hair sample collected at enrollment and/or self-report use 
 3 C. trachomatis, N. gonorrhoeae, syphilis, genital warts, Trichomonas vaginalis, and/or BV 
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Table 18. Odds of spontaneous abortion according to infection at enrollment 
Infection 
Women who experienced 
a SAB 
n=82 
n (%) 
Women who maintained 
their pregnancies 
n=134 
n (%) OR (95% CI) AOR (95% CI)1 
M. genitalium 
     Yes  
     No  
 
3 (3.7) 
79 (6.3) 
 
9 (6.7) 
125 (93.3) 
0.5 (0.1-2.0) 
 
0.6 (0.1-2.5) 
C. trachomatis 
     Yes  
     No  
 
3 (3.7) 
79 (6.3) 
 
12 (9.0) 
122 (91.0) 
0.4 (0.1-1.4) 
 
0.4 (0.1-1.6) 
1 Adjusted for age, history of SAB, smoking, and C. trachomatis or M. genitalium 
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 Table 19.  Odds of spontaneous abortion according to infection at enrollment, among women who did not 
report vaginal bleeding at enrollment 
 
Women who did not report  
vaginal bleeding at enrollment 
N=139 
Infection 
Cases 
N=35 
n(%) 
Controls 
N=104 
n(%) 
AOR 
(95% CI)1 
M. genitalium 
     Yes  
     No  
 
1 (2.9) 
34 (97.1) 
 
7 (6.7) 
97 (93.3) 
 
0.4 (0.1-3.8) 
C. trachomatis 
     Yes  
     No  
 
3 (8.6) 
32 (91.4) 
 
8 (7.7) 
96 (92.3) 
 
1.2 (0.3-5.1) 
1 Adjusted for age, history of SAB, smoking, and C. trachomatis or M. genitalium 
 
 
 82 
 Table 20.  Odds of spontaneous abortion according to infection at enrollment, stratified by gestational age at 
spontaneous abortion 
Infection 
Cases who experienced 
a SAB >11 weeks 
N=46 
n(%) 
 
Controls 
N=134 
n(%) 
AOR 
(95% CI)1 
Cases who experienced 
a SAB <11 weeks 
N=33 
n(%) 
 
Controls 
N=134 
n(%) 
AOR 
(95% CI)1 
M. genitalium 
     Yes  
     No  
 
2 (4.3) 
44 (95.7) 
 
9 (6.7) 
125 (93.3) 
 
0.6 (0.1-3.0) 
 
0 (0) 
33 (100) 
 
9 (6.7) 
125 (93.3) 
 
--- 
C. trachomatis 
     Yes  
     No  
 
2 (4.3) 
44 (95.7) 
 
12 (9.0) 
122 (91.0) 
 
0.5 (0.7-2.9) 
 
1 (3.0) 
32 (97.0) 
 
12 (9.0) 
122 (91.0) 
 
0.5 (0.1-4.0) 
1 Adjusted for age, history of SAB, smoking, and C. trachomatis or M. genitalium 
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Table 21. Characteristics of all study participants according to M. genitalium PCR result 
 
 
 
Characteristic 
M. genitalium 
positive 
n=12 
n (%) 
M. genitalium 
negative 
n=207 
n (%) 
 
 
 
OR (95% CI) 
Co-infection  
C. trachomatis 
     Yes 
     No 
 
 
1 (8.3) 
11 (91.7) 
 
 
14 (6.8) 
193 (93.2) 
 
 
1.3 (0.2-10.4) 
Demographic    
 Age 
     < 25 years 
     > 25 years 
 
10 (83.3) 
2 (16.7) 
 
133 (64.2) 
74 (35.8) 
 
2.8 (0.6-13.0) 
    
Race/Ethnicity 
     African American 
 
11 (91.7) 
 
184 (89.3) 
 
1.3 (0.2-10.7) 
    White/Other 1 (8.3) 22 (10.7)  
    
Marital Status    
     Unmarried 12 (100) 166 (80.2) --- 
     Married 0 41 (19.8)  
    
Education    
     < High school 5 (41.7) 72 (34.8) 0.7 (0.2-2.4) 
     ≥ High school 7 (58.3) 135 (65.2)  
Current Pregnancy History 
Mean gestational age1 (standard deviation) 
 
Vaginal bleeding at enrollment 
     Yes 
     No 
 
 
9.5 (2.9) 
 
 
4 (33.3) 
8 (66.7) 
9.2 (3.3)
 
 
74 (35.9) 
132 (64.1) 
 
---4 
 
 
0.9 (0.3-3.1) 
Vaginal bleeding since LMP    
     Yes 
     No 
5 (41.7) 
7 (58.3) 
101 (49.0) 
105 (51.0) 
0.7 (0.2-2.4) 
 
Alcohol use  
   
     Yes 
     No 
5 (41.7) 
7 (58.3) 
70 (33.8) 
137 (66.2) 
1.4 (0.4-4.6) 
 
Cigarette use  
   
     Yes 
     No 
6 (50.0) 
6 (50.) 
71/206 (34.5) 
135/206 (65.5) 
1.9 (0.6-6.1) 
 
Marijuana use 
   
     Yes 
     No 
 
4 (33.3) 
8 (66.7) 
40/206 (19.4) 
166/206 (80.6) 
2.1 (0.6-7.2) 
Crack/cocaine use2  
     Yes 
     No 
 
2 (20.0) 
8 (80.0) 
 
36 (24.3) 
112 (75.1) 
 
0.8 (0.2-3.8) 
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Table 21 continued 
 
N. gonorrhoeae    
     Yes 
     No 
 
0 (0) 
11 (100) 
1 (0.5) 
205 (99.5) 
--- 
Bacterial vaginosis 
     Yes 
     No 
 
0 (0) 
11 (100) 
 
9 (4.4) 
197 (95.6) 
--- 
Reproductive Health History    
Nulliparous 
     Yes 
     No 
 
 
5 (41.7) 
7 (58.3) 
 
36 (17.4) 
171 (82.6) 
 
3.4 (1.0-11.3) 
History of SAB    
     Yes 
     No 
 
1 (8.3) 
11 (91.7) 
68 (32.8) 
139 (67.2) 
0.2 (0.02-1.5) 
Prior ectopic pregnancy    
     Yes 
     No 
 
History of STD3 
     Yes 
     No 
 
History of C. trachomatis 
     Yes 
     No 
 
History of PID 
     Yes 
     No 
 
History of problems getting pregnant 
     Yes 
     No 
0 (0) 
7 (100) 
 
 
11 (100) 
0 (0) 
 
 
7 (63.6) 
4 (36.4) 
 
 
3 (27.3) 
7 (72.7) 
 
 
2 (18.2) 
9 (81.8) 
11 (6.4) 
160 (93.6) 
 
 
121 (59.6) 
82 (40.4) 
 
 
76 (36.9) 
130 (63.1) 
 
 
18 (8.8) 
187 (91.2) 
 
 
9 (4.4) 
197 (95.6) 
--- 
 
 
 
--- 
 
 
 
3.0 (0.9-10.6) 
 
 
 
3.9 (0.9-16.0) 
 
 
 
4.9 (0.9-25.9) 
 
* Missing observations: race, n=1; vaginal bleeding, n=1; cigarette smoking, n=1; marijuana use, n=1; crack/cocaine 
use, n=61; N. gonorrhoeae, n=2; BV, n=3; prior incompetent cervix, n=2; prior ectopic pregnancy, n=41; history of 
STD, n=5; history of PID, n=3; history of problems getting pregnant, n=2 
 
1 Gestational age in weeks 
2 Detected in hair sample collected at enrollment and/or self-reported use 
3 C. trachomatis, N. gonorrhoeae, syphilis, genital warts, Trichomonas vaginalis, and/or BV 
4 p-value=0.78 
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 Table 22.  Odds of M. genitalium infection adjusted for C. trachomatis PCR 
Characteristic AOR (95% CI) 
Nulliparous 3.4 (1.0-11.6) 
History of C. trachomatis 3.0 (0.8-10.5) 
History of PID 3.9 (0.9-16.1) 
History of problems getting pregnant 4.8 (0.9-25.7) 
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5.0  CONCLUSION 
In this study we used data from 2 cohorts of women at high risk of STDs and were able to examine three 
important features of M. genitalium infections in women, including: 1) the clinical characteristics; 2) the 
sociodemographic, sexual and behavioral correlates; and 3) the association with spontaneous abortion. 
The results from our study add to the growing literature on M. genitalium and suggest that women with 
M. genitalium present with few symptoms, have risk factors commonly associated with other STDs, are 
not at an increased risk of SAB, but report a history of reproductive morbidities. 
Our findings suggest that, among women with PID, women with M. genitalium do not present 
with strong clinical signs or symptoms and this symptomology is similar to that of C. trachomatis.  On 
the other hand, women with M. genitalium presented with fewer symptoms than women with gonococcal-
PID and had lower pelvic pain scores on average.  As symptoms may be mild, women with M. genitalium 
may not seek PID treatment.  Delayed care of PID increases  the risk of developing serious sequelae that 
often follows an episode of PID (186).  Therefore, identifying the risk factors associated with M. 
genitalium can help identify women at risk for infection or women that may have a less symptomatic 
infection.  In the PEACH cohort, M. genitalium cervical and/or endometrial infection was associated with 
young age, smoking and douching; variables that have been associated with other STDs and PID in 
previous studies.  Further, the demographic, sexual health and behavioral characteristics of women with 
M. genitalium were similar to women with C. trachomatis and/or N. gonorrhoeae.   
While the relationship between reproductive morbidities and M. genitalium is becoming better 
understood, the effects of M. genitalium in pregnancy have not been extensively studied.  In the EPS 
cohort of predominately young, unmarried, African-American pregnant women, M. genitalium did not 
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increase the risk of SAB, but was associated with several serious reproductive morbidities, including 
previous STDs, PID and problems getting pregnant.  Interestingly, the trends towards association 
remained after adjusting for C. trachomatis.  However, the cross-sectional design of our study and the 
small sample sizes of some of our sub-groups may have limited our findings.   Still, our findings support 
the need for further research on M. genitalium. 
 
5.1 FUTURE RESEARCH 
In our two study populations, M. genitalium was as prevalent as other STDs.  The relatively high 
prevalence of M. genitalium infection in these populations, along with its association with reproductive 
morbidities, raises important concerns about the importance of M. genitalium as a significant sexually 
transmitted infection. Further, as M. genitalium was strongly associated with having a concurrent C. 
trachomatis and/or N. gonorrhoeae infection, questions arise regarding the transmission of M. genitalium.  
That is, is M. genitalium an opportunistic organism, or does it pave the way for other STDs?  If it is 
indeed a pathogenic organism, then understanding the consequences of infection is important.  The long-
term sequelae of M. genitalium infection have been alluded to in previous studies that showed an 
association between M. genitalium, PID and tubal factor infertility, however, as these findings come from 
cross-sectional analyses of high-risk populations, future prospectively designed studies with larger sample 
sizes and appropriately chosen control groups are needed.  Such studies should further explore: 1) M. 
genitalium infection in asymptomatic individuals and the general population; 2) the relationship between 
M. genitalium and other STDs; 3) factors related to the persistence of M. genitalium infection; and 4) the 
long-term reproductive sequelae associated with persistent M. genitalium genital tract infections.  Such 
investigations should help explain factors associated with transmission of M. genitalium and the 
pathogenecity of this organism.  Still, even if M. genitalium is pathogenic, effective treatment options are 
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not yet available for women with M. genitalium PID.  Therefore, future randomized, controlled clinical 
trials should be designed to assess effective treatment options. The development of commercially 
available assay for M. genitalium detection is also needed in order to be able to screen those at risk for M. 
genitalium and to study M. genitalium outside of structured research settings.   
 
5.2 APPLICATION TO PUBLIC HEALTH 
Sexually transmitted diseases are prevalent, serious public health issues.  In fact, according to the CDC, 
the two most commonly-reported notifiable diseases (chlamydia and gonorrhea) in the U.S. are sexually 
transmitted (60).  STDs are a huge burden to the national health care system, costing an estimated $15.3 
billion annually (60). 
Women are more commonly infected with STDs and disproportionately suffer from the 
consequences of STDs compared to men (60).  In women, STDs can cause PID, a significant public 
health issue in the U.S. and worldwide.  PID is a common, costly condition, affecting nearly 8% of 
American women at some time in their lives.  Each year in the U.S. an estimated 1 million women are 
treated for PID.  Adverse sequelae, including tubal factor infertility, chronic pelvic pain, recurrent PID 
and ectopic pregnancy can occur if PID treatment is delayed or avoided.  Although PID is a polymicrobial 
disorder, non-gonococcal/non-chlamydial PID has not been studied extensively.  Therefore, studies of 
other possible organisms involved in PID are essential in order to decrease the incidence of this condition. 
M. genitalium has been identified as a possible etiologic agent of non-gonococcal/non-chlamydial 
PID (40, 42, 43, 104), and our study increased the understanding of M. genitalium PID.  We showed that 
M. genitalium infections tend not to produce strong symptoms in women with clinically suspected PID.   
We were also able to identify correlates associated with M. genitalium infections in women with PID.  
Due to the asymptomatic nature, M. genitalium lower and upper genital tract infections may go 
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undetected, which, left untreated, can lead to serious reproductive morbidity.   Therefore, identifying the 
factors associated with M. genitalium could help predict women at high risk of disease.  Further, 
screening for M. genitalium among high-risk women may help identify infected women, which may 
ultimately reduce PID and its sequelae. 
In addition to our findings related to M. genitalium and PID, our study provided an increased 
understanding of M. genitalium in adverse pregnancy outcomes.  Specifically, we were able to examine 
the association between M. genitalium and SAB, an area that has not been extensively studied.  SAB is 
the most common adverse outcome of pregnancy, occurring in an estimated 15% of clinically recognized 
pregnancies (117), and up to 50% of all pregnancies (118).  SABs are another important public health 
issue, for they cause considerable maternal psychological and physical morbidity and impart substantial 
costs to healthcare systems (147, 187).  Our study was the first to prospectively examine the role of M. 
genitalium in SAB among a high-risk pregnant population and adds to the growing literature on the role 
of M. genitalium on reproductive health. 
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APPENDIX A: SUPPLEMENTARY TABLES FOR MANUSCRIPT 1 
Table 23. Unadjusted and adjusted p-values for the clinical characteristics of women with M. genitalium (Mg) 
only, women with N. gonorrhoeae (Gc) only and women with M. genitalium and N. gonorrhoeae enrolled in 
the PEACH Study 
 
Unadjusted 
p- value 
Adjusted 
p-valuea 
Unadjusted 
p- value 
Adjusted 
p-valueb 
Presenting Complaints 
     Nausea/vomiting   
     Non-menstrual vaginal bleeding 
     Heavier menstrual bleeding 
     Bleeding during or after sex 
     Abnormal vaginal discharge 
     More frequent urination  
0.68 
0.79 
0.38 
0.23 
0.73 
0.50 
0.56 
0.75 
0.29 
0.10 
0.67 
0.22 
0.48 
0.24 
0.77 
0.63 
0.18 
0.17 
0.52 
0.24 
0.42 
0.93 
0.45 
0.14 
Markers of Inflammation 
     Elevated temperature ( >101o F) 
     Elevated white blood cell count ( >10,000 mm3 ) 
     Erythrocyte Sedimentation Rate ( >15 mm/hr) 
     C-Reactive Protein ( >5mg/dL) 
     Bilateral adnexal tenderness 
0.08 
0.02 
0.002 
0.30 
0.59 
0.10 
0.01 
0.01 
0.48 
0.51 
0.68 
0.13 
0.43 
0.97 
0.26 
0.28 
0.51 
0.49 
0.36 
0.42 
Mucopurulent cervicitis 0.001 0.01 0.02 0.01 
BV by Gram Stainc 0.11 --- 0.54 --- 
Amsel’s Criteria     
     BV by Amsel’s criteria 
     Discharge consistent with BV 
     Vaginal pH >4.5 
     Positive whiff test 
     Clue cells >20% 
0.82 
0.06 
0.02 
0.92 
0.53 
0.42 
0.09 
0.09 
0.88 
0.83 
1.00 
0.79 
0.39 
0.17 
0.75 
0.77 
0.97 
0.96 
0.11 
0.92 
a p-value adjusted for BV (Mg+/Gc-/Ct- vs. Gc+/Mg-/Ct-) 
b p-value adjusted for BV (Gc+/Mg-/Ct- vs. Gc+/Mg+/Ct-) 
c Normal or intermediate vs. BV flora 
d Mean composite pain score= (mean of current pelvic pain score, average pelvic pain score and worst pelvic pain 
score) X 10 
e sd=standard deviation 
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Table 24.  Unadjusted and adjusted p-values for the clinical characteristics of women with M. genitalium 
(Mg) only, women with C. trachomatis (Ct) only, and women with M. genitalium and C. trachomatis enrolled 
in the PEACH Study 
 
Unadjsuted 
p- value 
Adjusted 
p-valuea 
Unadjsuted 
p- value 
Adjusted 
p-valueb 
Presenting Complaints 
     Nausea/vomiting   
     Non-menstrual vaginal bleeding 
     Heavier menstrual bleeding 
     Bleeding during or after sex 
     Abnormal vaginal discharge 
     More frequent urination  
0.93 
0.19 
0.55 
0.44 
0.54 
0.80 
0.94 
0.25 
0.55 
0.41 
0.57 
0.63 
1.00 
0.49 
0.24 
0.43 
0.68 
0.63 
0.81 
0.38 
0.16 
0.40 
0.85 
0.73 
Markers of Inflammation 
     Elevated temperature ( >101o F) 
     Elevated white blood cell count ( >10,000 mm3 ) 
     Erythrocyte Sedimentation Rate ( >15 mm/hr) 
     C-Reactive Protein ( >5mg/dL) 
     Bilateral adnexal tenderness 
--- 
0.72 
0.12 
0.27 
0.96 
--- 
0.76 
0.16 
0.24 
0.98 
0.14 
0.99 
0.18 
0.16 
1.00 
0.06 
0.58 
0.26 
0.16 
0.88 
Mucopurulent cervicitis 0.72 0.74 0.43 0.57 
BV by Gram Stainc 0.63 --- 0.45 --- 
Amsel’s Criteria     
     BV by Amsel’s criteria 
     Discharge consistent with BV 
     Vaginal pH >4.5 
     Positive whiff test 
     Clue cells >20% 
0.58 
0.53 
0.08 
0.67 
0.67 
0.55 
0.74 
0.12 
0.63 
0.78 
0.67 
0.39 
0.21 
0.13 
0.27 
0.75 
0.451 
0.40 
0.15 
0.35 
a p-value adjusted for BV (Mg+/Gc-/Ct- vs. Ct+/Mg-/Gc-) 
b p-value adjusted for BV (Ct+/Mg-/Gc- vs. Ct+/Mg+/Gc-) 
c Normal or intermediate vs. BV flora 
d Mean composite pain score= (mean of current pelvic pain score, average pelvic pain score and worst pelvic pain 
score) X 10 
e sd=standard deviation 
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APPENDIX B: SUPPLEMENTARY TABLES FOR MANUSCRIPT 2 
Table 25. Characteristics of PEACH Study participants and association with M. genitalium cervical infection 
 
 
Characteristic 
M. genitalium 
positive 
n (%)1 
M. genitalium 
negative 
n (%)1 
 
 
OR (95% CI) 
Demographic    
Age  
     < 25 years 
 
63 (14.1) 
 
384 (85.9) 
 
3.3 (1.7-6.5) 
     >25 years 
 
Race/Ethnicity 
11 (4.7) 224 (95.3)  
     African-American  
     White/Hispanic/Other 
55 (10.8) 
19 (11.0) 
454 (89.2) 
154 (89.0) 
0.9 (0.6-1.7) 
 
Marital Status 
   
     Unmarried 
     Married 
60 (10.7) 
5 (7.2) 
499 (89.3) 
64 (92.7) 
1.5 (0.6-3.9) 
 
Education 
   
     < High school  
     > High school 
33 (12.5) 
41 (9.9) 
231 (87.5) 
375 (90.1) 
1.3 (0.8-2.1) 
Sexual  Health    
Sexually active     
     Yes 
     No 
68 (11.8) 
6 (5.8) 
510 (88.2) 
98 (94.2) 
2.2 (0.9-5.2) 
 
≥ 2 life time sexual partners  
   
     Yes 
     No 
10 (15.6) 
64 (10.4) 
54 (84.4) 
554 (89.6) 
1.6 (0.8-3.3) 
 
New sexual partner in past month 
   
     Yes 
     No 
9 (14.1) 
65 (10.5) 
55 (85.9) 
553 (89.5) 
1.4 (0.7-2.9) 
 
History of STD3 
   
     Yes 
     No 
43 (10.5) 
31 (11.7) 
366 (89.5) 
234 (88.3) 
0.9 (0.5-1.4) 
 
History of BV 
   
     Yes 
     No 
12 (7.9) 
60 (11.8) 
139 (92.1) 
450 (88.2) 
0.6 (0.3-1.2) 
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Table 25 continued 
 
 
History of PID 
   
     Yes 
     No 
19 (9.1) 
54 (11.6) 
190 (90.9) 
411 (88.4) 
0.8 (0.4-1.3) 
 
Hormonal contraception use 
   
     Yes 
     No 
16 (12.5) 
52 (11.6) 
112 (87.5) 
398 (88.4) 
1.1 (0.6-2.) 
 
Rare/occasional condom use4 
   
     Yes 
     No 
51 (12.6) 
17 (9.9) 
355 (87.4) 
155 (90.1) 
1.3 (0.7-2.3) 
 
Consistent condom use5 
   
     Yes 
     No 
7 (9.3) 
61 (12.1) 
68 (90.7) 
442 (87.9) 
1.8 (0.7-4.7) 
 
Oral sex 
   
     Yes 
     No 
22 (14.0) 
50 (10.3) 
135 (86.0) 
434 (89.7) 
1.4 (0.8-2.4) 
 
Anal sex 
   
     Yes 
     No 
4 (18.2) 
70 (10.6) 
18 (81.8) 
590 (89.4) 
1.9 (0.6-5.7) 
 
Age at sexual debut 
     < 15 years 
     > 15 years 
 
 
41 (11.7) 
33 (10.0) 
 
 
310 (88.3) 
298 (90.0) 
 
 
1.2 (0.7-1.9) 
Behavioral    
Vaginal douche > 2 times in past month     
     Yes 
     No 
21 (16.1) 
53 (9.6) 
109 (83.8) 
499 (90.4) 
1.8 (1.0-3.1) 
 
Drug use  
   
     Yes 
     No 
 
29 (15.3) 
45 (9.2) 
161 (84.7) 
443 (90.8) 
1.8 (1.1-2.9) 
Current smoker    
     Yes 
     No 
43 (14.7) 
31 (8.0) 
250 (85.3) 
354 (91.9) 
2.0 (1.2-3.2) 
 
Alcohol use 
   
     Yes 
     No 
41 (10.8) 
33 (11.0) 
338 (89.2) 
266 (89.0) 
1.0 (0.6-1.6) 
 
Alcohol drinks per week 
     > 7 drinks 
     < 7 drinks 
 
 
11 (13.4) 
63 (10.6) 
 
 
71 (86.6) 
533 (89.4) 
 
 
1.3 (0.7-2.6) 
1 % of total study population with characteristic that tested positive for M. genitalium;  
2 Normal or intermediate vaginal flora vs. BV flora;  
3 History of N. gonorrhoeae, C. trachomatis, or Trichonomas vaginalis;  
4 Condoms used 0 to 5 out of 10 sexual encounters;  
5 Condoms used 10 out of 10 sexual encounters 
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Table 26.  Characteristics of PEACH Study participants and association with M. genitalium endometrial 
infection 
 
 
Characteristic 
M. genitalium 
positive 
n (%)1 
M. genitalium 
negative 
n (%)1 
 
 
OR (95% CI) 
Demographic    
Age  
     < 25 years 
 
41 (10.0) 
 
362 (90.0) 
 
2.5 (1.2-5.3) 
     >25 years 
 
Race/Ethnicity 
9 (4.3) 199 (35.5)  
     African-American  
     White/Hispanic/Other 
42 (9.5) 
8 (4.7) 
399 (71.1) 
162 (95.3) 
2.1 (0.98-4.6) 
 
 
Marital Status 
 
 
  
     Unmarried 39 (7.8) 461 (92.2) 1.2 (0.43-3.6) 
     Married 
 
Education 
   
     < High school  
     > High school 
22 (9.3) 
28 (7.5) 
215 (38.4) 
345 (61.6) 
1.3 (0.70-2.3) 
Sexual Health 
Sexually active  
   
     Yes 
     No 
 
42 (8.2) 
8 (8.2) 
471 (91.8) 
90 (91.8) 
1.0 (0.5-2.2) 
 
≥ 2 life time sexual partners     
     Yes 
     No 
 
6 (10) 
44 (8) 
54 (92.0) 
507 (90.4) 
1.3 (0.5-3.1) 
New sexual partner in past month    
     Yes 
     No 
 
6 (9.4) 
44 (8.0) 
58 (10.3) 
503 (92.0) 
1.2 (0.5-2.9) 
History of STD3    
     Yes 
     No 
 
29 (8.1) 
20 (8.1) 
330 (91.9) 
226 (91.9) 
1.2 (0.5-2.9) 
History of BV    
     Yes 
     No 
 
8 (5.7) 
42 (9.2) 
132 (94.3) 
412 (90.7) 
0.6 (0.3-1.3) 
History of PID    
     Yes 
     No 
 
12 (6.3) 
38 (9.1) 
177 (93.7) 
378 (90.9) 
0.7 (0.3-1.3) 
Hormonal contraception use    
     Yes 
     No 
 
9 (8.1) 102 (91.9) 1.0 (0.5-2.1) 
Rare/occasional condom use4    
     Yes 
     No 
33 (9.2) 
9 (5.8) 
326 (90.8) 
145 (94.2) 
1.6 (0.8-3.5) 
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Table 26 continued 
Consistent condom use5    
     Yes 
     No 
 
3 (4.5) 
39 (8.7) 
64 (95.5) 
407 (91.3) 
0.7 (0.3-1.9) 
Oral sex    
     Yes 
     No 
 
11 (7.9) 
39 (8.9) 
128 (92.1) 
397 (91.1) 
0.9 (0.4-1.8) 
Anal sex    
     Yes 
     No 
 
3 (14.3) 
47 (14.3) 
18 (85.7) 
543 (92.0) 
1.9 (0.6-6.8) 
Age at sexual debut 
     < 15 years 
     > 15 years 
 
29 (9.1) 
21 (7.2) 
 
289 (90.9) 
272 (92.8) 
 
1.3 (0.7-2.3) 
Behavioral 
Vaginal douche > 2 times in past month  
   
     Yes 
     No 
 
17 (14.3) 
33 (6.7) 
102 (85.7) 
459 (93.3) 
2.3 (1.2-4.3) 
 
Drug use     
     Yes 
     No 
 
22 (13.0) 
28 (6.4) 
147 (87.0) 
411 (73.7) 
2.2 (1.2-3.9) 
Current smoker    
     Yes 
     No 
 
28 (10.7) 
22 (6.4) 
234 (89.3) 
324 (93.6) 
1.8 (0.9-3.2) 
Alcohol use    
     Yes 
     No 
 
27 (7.9) 
23 (8.6) 
314 (7.9) 
244 (43.7) 
0.9 (0.5-1.6) 
Alcohol drinks per week 
     > 7 drinks 
     < 7 drinks 
 
8 (11.0) 
42 (7.8) 
 
65 (89.0) 
493 (92.1) 
 
1.4 (0.6-3.2) 
1 % of total study population with characteristic  
2 Normal or intermediate vaginal flora vs. BV flora;  
3 History of N. gonorrhoeae, C. trachomatis, or Trichonomas vaginalis;  
4 Condoms used 0 to 5 out of 10 sexual encounters;  
5 Condoms used 10 out of 10 sexual encounters 
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APPENDIX C: SUPPLEMENTARY TABLES FOR MANUSCRIPT 3 
 
Table 27.  Odds of spontaneous abortion according to infection at enrollment among participants in the Early 
Pregnancy Study 
Infection OR (95% CI) AOR (95% CI)1 AOR (95% CI)2 AOR (95% CI)3
M. genitalium  0.5 (0.1-2.0) 0.6 (0.1-2.5) 0.5 (0.1-2.0) 06 (0.2-2.3) 
C. trachomatis  0.4 (0.1-1.4) 0.4 (0.1-1.6) 0.4 (0.1-1.4) 0.4 (0.1-1.6) 
1 Adjusted for age, history of SAB, smoking, cocaine use and C. trachomatis or M. genitalium PCR 
2 Adjusted for age, smoking, and C. trachomatis or M. genitalium PCR 
3 Adjusted for age, history of SAB, smoking, alcohol use and C. trachomatis or M. genitalium PCR 
 
 
 
 
 
 
 
Table 28.  Unadjusted odds of spontaneous abortion among participants in the Early Pregnancy Study 
Characteristic OR (95% CI) 
Previous SAB 1.9 (1.1-3.4) 
Smoking 1.3 (0.7-2.3) 
Cocaine use 1.2 (0.5-2.4) 
Alcohol use 1.2 (0.7-21) 
Maternal Age 1.1 (0.5-2.2) 
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